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RIASSUNTO
I  peptidi  antimicrobici  cationici  (CAMPs,  cationic  antimicrobial  peptides)  sono  piccoli 
peptidi (15-50 residui) che esercitano una azione battericida diretta e costituiscono l'arma 
più antica del sistema immunitario innato degli  eucarioti multicellulari.  Queste molecole 
possiedono una carica netta positiva ed acquisiscono una struttura anfipatica, che rende 
possibile  la  loro  interazione  con  la  membrana  plasmatica,  destabilizzando  la  sua 
architettura e/o creando pori.  I  CAMPs sono promettenti  agenti  terapeutici  ed il  nostro 
gruppo di ricerca è focalizzato sullo sviluppo di nuovi CAMPs diretti contro i patogeni più 
comuni nelle infezioni polmonari dei malati di fibrosi cistica. Negli scorsi anni, sono state 
scoperte diverse proteine che mostrano un'attività antibatterica non correlata con la loro 
funzione primaria; queste proteine sembrano agire da trasportatrici, nella loro sequenza, di  
CAMPs criptici, che potrebbero essere rilasciati dall'azione di proteasi umane o batteriche.
I principali scopi di questo lavoro sono (1) lo sviluppo di un nuovo sistema di punteggio per 
l'identificazione di peptidi antimicrobici criptici nelle sequenze proteiche, (2) lo sviluppo e 
l'ottimizzazione di un costrutto di fusione per l'espressione dei nuovi CAMPs ed infine (3) 
l'elaborazione di strategie di  modelling di  CAMPs attraverso simulazioni Monte Carlo e 
funzioni di solvatazione implicita.
Per quanto riguarda il primo scopo, abbiamo sviluppato funzioni di punteggio basate sulla 
carica e sulla idrofobicità, due caratteristiche universalmente riconosciute come essenziali 
per  l'attività  antimicrobica.  La  sostanziale  novità  del  nostro  sistema di  punteggio  è  la 
presenza di variabili ceppo-specifiche che possono essere calcolate utilizzando i dati di  
attività antimicrobica di un set di peptidi saggiato sui ceppi batterici di interesse. Le nostre  
funzioni  di  punteggio,  quindi,  possono  essere  “regolate”  al  fine  di  identificare  CAMPs 
particolarmente attivi contro il ceppo di interesse.
Una validazione preliminare del sistema di punteggio è stata condotta  in silico mediante 
l'analisi  di  un pannello di  proteine contenenti  peptidi  antimicrobici  criptici  noti;  il  nostro  
sistema ha identificato quasi tutti i  CAMPs criptici noti. Alcuni nuovi putativi CAMPs sono 
già stati prodotti con un nuovo sistema di espressione ricombinante in Escherichia coli. Il 
sistema è costituito da un costrutto di fusione dove la sequenza codificante il peptide è 
localizzata a valle di un  carrier, l'onconasi, una ribonucleasi capace di formare corpi di 
inclusione  con  elevata  efficienza  e  resa.  I  corpi  di  inclusione  sequestrano  il  peptide 
antimicrobico, mascherando quindi la sua tossicità verso al cellula batterica. L'onconasi ed 
il peptide sono uniti da un linker che contiene il dipeptide Asp-Pro, capace di idrolizzarsi 
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spontaneamente in condizione relativamente blande di temperatura e pH.
Il costrutto di fusione è stato testato clonando il peptide criptico già noto della trombina 
umana  (ThrAP,  thrombin  antimicrobial  peptide)  ed  ottimizzato  con  diverse  mutazioni 
puntiformi al  fine di  abolire siti  di  taglio interni.  La versione finale contiene anche una 
sequenze di  istidine  che  permette  di  purificare  in  un  singolo  passaggio  il  costrutto  di  
fusione. Il peptide è stato invece purificato sfruttando la sua diversa solubilità, rispetto al 
costrutto di fusione, a pH neutro. L'espressione è stata condotta in un nuovo mezzo di 
coltura dalla composizione semi-definita e si è avuta una resa pari  a circa 7-10 mg di 
peptide  puro  da  un  litro  di  coltura.  Un  nuovo  peptide  antimicrobico  identificato  nella 
apolipoproteina  E  (ApoE-AP,  apolipoprotein  E  antimicrobial  peptide)  è  stato  prodotto 
attraverso la stessa strategia. I due peptidi ricombinanti sono stati caratterizzati mediante 
dicroismo circolare;  in  tampone  sono  apparsi  privi  di  una  struttura  definita,  mentre  in 
presenza di agenti che mimano un ambiente di membrana hanno acquisito una struttura 
elicoidale. Inoltre, è stata osservata una possibile interazione tra ThrAP e due molecole di 
grande importanza da un punto di vista biologico, il lipopolisaccaride e l'alginato.
Infine,  sono  stati  effettuati  studi  computazionali  allo  scopo  di  identificare  funzioni  di 
solvatazione  implicita  che  potessero  simulare  strutture  sperimentali  di  CAMPs;  la 
conformazione di peptidi le cui strutture sono state risolte in presenza di micelle (SDS o 
DPC) e TFE è stata modellata con la strategia Monte Carlo nel vuoto, in acqua implicita, in 
ottanolo  implicito  ed  in  ottanolo  implicito  con attenuazioni  dell'energia  di  solvatazione. 
Quest'ultima  condizione  è  stata  considerata  per  creare  una  sorta  di  ambiente  che 
mimasse  una  membrana.  Le  simulazioni  hanno  mostrato  che  le  strutture  risolte  in 
presenza di micelle vengono più correttamente simulate con la solvatazione da ottanolo 
“attenuata”, mentre le strutture risolte in presenza di TFE sono spesso simulate meglio nel  
vuoto.
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SUMMARY
Cationic AntiMicrobial Peptides (CAMPs) are small peptides (15-50 residues) which exert 
a direct microbicidal activity and constitute the most ancient arm of the innate immune 
system of multicellular eukaryotes. They possess a positive net charge and acquire an 
amphipathic structure, which permits their interaction with the cell membrane, destabilizing 
its architecture and/or creating pores. CAMPs are promising therapeutic agents and our 
research group is focused on the development of new CAMPs against the most common 
pathogens  in  the  lung  infections  of  cystic  fibrosis  patients.  In  the  last  years,  several 
proteins which show antibacterial activity not correlated with their primary function have 
been  discovered;  these  proteins  seem to  act  as  carriers  in  their  primary  structure  of 
“cryptic” CAMPs, that could be released by the action of human or bacterial proteases.
The main aims of this research work are (1) the development of a novel scoring system for  
the  identification  of  “cryptic”  antimicrobial  peptides  in  protein  sequences,  (2)  the 
development and optimization of a fusion construct for the preparation of the novel CAMPs 
and  (3)  the  development  of  modelling  strategies  of  CAMPs  through  Monte  Carlo 
simulations and implicit solvation energy functions.
As  for  the  first  aim,  we  have  developed  scoring  functions  based  on  charge  and 
hydrophobicity, two characteristics universally recognized as essential for the antimicrobial 
activity. The main novelty of our scoring system is the presence of strain-specific variables 
which can be estimated using antimicrobial activity data of a set of peptides assayed on 
bacterial strains of interest. Thus our scoring functions can be tuned to identify CAMPs 
particularly active against the strain of interest.
A preliminary in silico validation of the scoring system was conducted through the analysis 
of  a panel  of  protein sequences containing known cryptic antimicrobial  fragments. Our 
system was able to identify almost all the antibacterial fragments. Several newly identified 
putative CAMPs were already produced with a novel recombinant expression system in 
Escherichia coli.  This system is constituted by a fusion construct where the sequence 
coding the peptide is located downstream a carrier, onconase, a ribonuclease capable of 
forming inclusion bodies with  high efficiency and yield.  Inclusion bodies sequester  the 
CAMP thus abolishing its toxicity towards the bacterial cell. Onconase and the peptide are 
joined  by  a  linker  which  contains  the  dipeptide  Asp-Pro  which  undergo  spontaneous 
hydrolysis in relative mild conditions of temperature and pH.
The  fusion  construct  was  tested  cloning  the  already  known  cryptic  CAMP of  human 
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thrombin  (ThrAP,  thrombin  antimicrobial  peptide)  and  optimized  with  several  point 
mutations in order to abolish internal sites of cleavage which were discovered. The final 
optimized version contains also a tag of histidines which permits a one-step purification of  
the fusion construct. The peptide was instead purified by exploiting its different solubility at 
neutral pH with respect to the fusion construct. The expression was conducted in a novel  
semi-defined rich medium and a final yield of about 7-10 mg of pure peptide from one liter  
of culture was obtained. A novel CAMP identified in human apolipoprotein E, ApoE-AP 
(apolipoprotein E-antimicrobial  peptide) was produced with the same strategy. The two 
recombinant  peptides  displayed  antibacterial  activity  towards  both  Gram-negative  and 
Gram-positive bacteria. The peptides underwent a preliminary structural characterization 
by means of circular dichroism; they were unstructured in buffer, but acquired a helical  
structure in membrane-mimicking environments. Moreover, a putative interaction between 
ThrAP and two molecules of great biological relevance, LPS and alginate, was observed.
Finally, computational studies were performed with the aim of identifying solvation energy 
functions which simulate experimental structures of CAMPs; the conformation of peptides 
whose structures were solved in the presence of micelles (SDS or DPC) and TFE was 
modeled  using  a  Monte  Carlo  strategy in  vacuum,  implicit  water,  implicit  octanol  and 
implicit octanol with attenuations of the solvation energy. The last condition was employed 
in order to re-create a sort of membrane-like environment. The simulations showed that 
structures solved in the presence of micelles are better simulated with the “attenuated” 
octanol  solvation,  whereas,  structures  solved in  the  presence of  TFE are  often  better 
simulated in vacuum.
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ABBREVIATIONS
aa. amino acids
AMAC ammonium acetate
ApoE-AP Apolipoprotein E-antimicrobial peptide
ASA accessible surface area
BPA 3-bromopropylamine
BSA bovine serum albumin
CAMP cationic antimicrobial peptide
CD circular dichroism
DPC dodecylphosphocholine
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EEF-1 effective energy function-1
GuHCl guanidinium chloride
HPLC high-pressure liquid cromatography
hRNase 4-CAM carboxamido-methyl-human ribonuclease 4
hRNase 4-PA propylamine-human ribonuclease 4
hRNase 4-PE pyridine-ethyl-human ribonuclease 4
IAA iodoacetamide
IC50 half maximal inhibitory concentration
IMAC immobilized metal-affinity chromatography
IPTG Isopropyl β-D-1-thiogalactopyranoside 
LPS lipopolysaccharide/s
Lyz-CAM carboxamido-methyl-lysozyme
Lyz-PA propylamine-lysozyme
Lyz-PE pyridine-ethyl-lysozyme
MC Monte Carlo
MD molecular dynamics
MES 2-(N-morpholino)ethanesulfonic acid
MIC minimum inhibitory concentration
NaP sodium-phosphate
NMR nuclear magnetic resonance
OD optical density
ONC onconase
PDB Protein Data Bank
QSAR quantity structure-activity relationship
RMSD root-mean-square deviation
RNase/hRNase ribonuclease/human ribonuclease
rpm revolutions per minute 
SD standard deviation
SDRM semi-defined rich medium
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel 
electrophoresis
SEC solvation energy coefficien
SUMO small ubiquitin-related modifier
TEV Tobacco Etch Virus
TFE 2,2,2-trifluoroethanol
ThrAP Thrombin-antimicrobial peptide
TSA trypticase soy agar
VP 4-vinylpyridine
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1. INTRODUCTION
1.1 General properties of cationic antimicrobial peptides (CAMPs)
Cationic  antimicrobial  peptides  (CAMPs)  constitute  the  most  ancient  arm of  the  host-
defense system and are thus widely diffused in nature, from bacteria to mammals. These 
molecules are able to exert a direct antimicrobial, antiviral and antifungin activity and their  
length  usually  spans  from  10  to  50  residues.  Regarding  their  structure,  CAMPs  are 
divided in three different classes: α-helical peptides, like magainins and mellitin, globular  
peptides with  β-sheets linked by disulphide bridges and finally peptides without a  well 
defined structure, which are often enriched in amino acids like proline, tryptophan, histidine 
or glycine (Figure 1).
Figure 1: examples of the three different structural classes of CAMPs. A: human LL-37 bound to 
SDS micelles (PDB code: 2K6O); B: human β-defensin 2 (PDB code: 1E4Q); C: bovine indolicidin 
bound to SDS micelles (PDB code: 1G8C).
CAMPs, as their name suggests,  have a positive net charge due to the abundance in 
lysines and arginines and are rich in hydrophobic residues; they are consequently able to  
acquire an amphipatic structure which allow them to perturb the bacterial  membranes, 
their  main  target,  leading  to  cell  death.  Bacterial  membranes  possess  anionic 
phospholipids and thus the electrostatic interaction between CAMPs and these lipids can 
be  easily  imagined;  in  eukaryotic  membranes,  instead,  anionic  phospholipids  are 
sequestered  in  the  inner  leaflet  and  thus  no  electrostatic  interactions  can  be  formed 
(Wiesner J. and Vilcinskas A., 2010). This important physicochemical characteristic is the 
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basis of the selectivity of cationic antimicrobial peptides towards bacteria (Figure 2).
Figure 2: representation of the basis of specificity of CAMPs (from Zasloff M., 2002).
If we consider the emerging of multi-drug resistant pathogens in the last years, cationic 
antimicrobial peptides are very promising therapeutic agents, because the induction of a 
form of resistance is  very unlikely, as bacteria should drastically change the membrane 
architecture. However, some “transient” forms of resistance have been described, like the 
modification  of  cell  wall  components  in  order  to  reduce  the  negative  net  charge,  the 
increase of membrane rigidity, the production of a polysaccharide capsule which may act  
as a shield or even the alteration of the expression of CAMPs in the host (Guilhelmelli F. et 
al., 2013). Moreover, the biofilm produced by some bacteria like Pseudomonas aeruginosa 
can reduce the action of antimicrobial peptides. For example, Chan C.  et al., (2004 and 
2005)  demonstrated  that  the  exopolysaccharide  alginate,  the  major  component  of  the 
biofilm, can act as an auxiliary membrane, binding CAMPs and inducing their aggregation.
CAMPs  are  active  also  on  resting  bacteria,  whereas  commonly  used antibiotics  are 
instead only active on dividing cells. Finally, there are many reports of additional biological 
activities of these peptides, like immunomodulation, wound healing and anticancer activity 
(Pushpanathan M. et al., 2013). An example of immunomodulation is the ability to inhibit 
lipopolysaccharide  (LPS)-induced  pro-inflammatory  cytokine  production.  LPS  is  an 
endotoxin  localized  on  the  external  membrane  of  Gram-negative  bacteria  and 
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characterized by an amphiphilic structure, with an hydrophobic portion, lipid A, and an 
hydrophilic moiety, divided into a polysaccharide part and antigen “O”, with several repeats 
of  variable  oligosaccharide  units.  Different  CAMPs  are  able  to  bind  LPS  aggregates, 
making them “invisible” to transduction pathways that once activated lead to inflammation 
and even septic shock. The binding is driven by the cationic residues of the peptide, which 
interact with the phosphate groups of lipid A, while hydrophobic residues are located in the 
lipophilic core region; in addition, aromatic residues play a fundamental role because they 
stabilize  a  packed structure,  that  can also  facilitate  the  translocation  across  the  outer 
membrane in order to reach the plasma membrane (Pulido D. et al., 2011).
Among the main drawbacks of CAMPs, we find the haemolytic activity, usually observed in 
particularly  hydrophobic  and  amphiphilic  peptides,  and  the  susceptibility  to  proteolytic 
degradation (Aoki W. and Ueda M., 2013).
1.2 Models of action
CAMPs are able to perturb and even destroy bacterial membranes, leading to cell death 
for the disruption of the electrochemical gradient, the loss of metabolites and the final lysis. 
The exact  mechanism of  membrane perturbation and/or  disruption is  still  not  perfectly 
clear even if many experimental and computational works have tried to shed more light. 
Three models have been proposed: the barrel-stave model, the toroidal model and the 
carpet model. According to the barrel-stave model, the peptides insert into the membrane 
creating a pore which they line; in the toroidal model, the peptides create a toroidal pore, 
which is lined also by the phospholipids' heads; finally, in the carpet model, the peptides 
interact with  the membrane surface and,  when a critical  concentration is  reached,  the 
membrane  is  destroyed  with  the  formation  of  micelles  and  lipid-peptides  aggregates 
(Figure 3).
Figure 3: representation of the three proposed mechanisms of membrane perturbation. A: barrel-
stave model; B: carpet model; C: toroidal model (from Tang M. and Hong M., 2009).
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More recently, new models arose from the experimental observations of  peptide-induced 
lipid segregation of anionic components from zwitterionic lipids (Figure 4); in detail, anionic 
lipids are clustered and consequently biophysical and biological alterations occur, like the 
modification of membrane curvature, which can alter cell division or sporulation, or the loss 
of functionality of protein-lipid complexes with important physiological properties (Teixeira 
V. et al., 2012).
Figure 4: representation of the segregation of anionic lipids (in  red) from zwitterionic ones (in 
yellow) induced by CAMPs (in blue) (from Teixeira V. et al., 2012).
1.3 Structural studies of CAMPs
The structure of CAMPs has been studied using a variegated panel of both experimental  
and computational techniques. Structural studies are aimed to elucidate the structure of 
peptides in presence of different kinds of micelles (usually anionic, like  SDS, to mimic a 
bacterial membrane or zwitterionic, like DPC, to mimic instead the eukaryotic membrane), 
lipid bilayers and also the structure of pores and the dynamic of their formation.
Experimental  studies  performed  with  circular  dichroism  focus  on  the  study  of  the 
secondary structure of the peptides in aqueous buffers alone and in presence of micelles 
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and possible ligands like lipopolysaccharide and alginate (Chan C. et al., 2004; Gopal R. 
et al., 2012). Globular peptides with β-sheets are structured in water (Munyuki G.  et al., 
2013), while instead α-elical peptides are usually unordered, possessing a typical random-
coil  spectrum,  but  micelles  and  ligands  are  able  to  induce  an  helicoidal  structure.  In 
particular, the structuring observed in presence of LPS is very important, as the binding to  
this molecule is a prerequisite for a possible detoxifying activity. Experiments with circular 
dichroism are often conducted in presence of trifluoroethanol, an agent able to induce α-
helix (Roccatano D.  et al., 2002), in order to create a membrane-mimicking environment 
and to evaluate the propensity to acquire an ordered structure.
Solution NMR permits to solve the tertiary structure of CAMPs and is generally performed 
in presence of SDS or DPC micelles, trifluoroethanol and also lipopolysaccharide. Solid-
state  NMR  gives  instead  a  more  realistic  image  of  the  membrane  interactions  of 
antimicrobial  peptides, because it  allows the study of CAMPs in the presence of liquid 
disordered phospholipid bilayers and gives information also on the dynamics and phase 
properties of lipids (Bechinger B. and Salnikov E. S., 2012).
Finally,  force atomic microscopy is an experimental  technique recently used to  directly 
visualize  the  formation  and  the  progressive  lateral  expansion  of  membrane  pores 
(Rakowska P. D. et al., 2013).
Computational techniques are employed to study at an atomic-level the perturbation of 
lipid bilayers by antimicrobial peptides or their interaction with micelles. Micelles mimic the 
main  physicochemical  property  of  a  membrane:  the  presence of  an  hydrophobic  core 
surrounded by an hydrophilic shell. They posses lower relaxation times than lipid bilayers 
and provide a direct link to NMR spectroscopy; however, they have an higher degree of 
curvature, a different chain structure than biological relevant lipids and could more easily 
deform. On the other hand,  the more realistic modelling in lipid bilayers is biased by the 
choice of the initial position and orientation of the peptide and the accurate sampling of the  
phase space can be a challenge (Mátyus E. et al., 2007; Langham A. and Kaznessis Y. N., 
2010). Different molecular dynamics (MD) simulations pointed out that CAMPs bind more 
strongly to membrane pores, stabilizing them (Mihajlovic M. and Lazaridis T., 2010; Lam K. 
L. H. et al. 2012; He Y. et al., 2013). Moreover, MD permitted to observe the spontaneous 
formation  of  toroidal  pores  which  appeared disordered,  without  a  regular  packing  and 
orientation of the peptides, in contrast with the classical cylindrical model (Sengupta D. et 
al., 2008) (Figure 5).
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Figure 5: on the left,  cartoon image which shows the difference between the disordered toroidal 
pore and the “classical” ordered model; on the right, snapshot of the disordered toroidal pore from 
the MD simulation (from Sengupta D. et al., 2008).
Finally, MD studies have also shown a correlation between peptides' haemolytic activity 
and  the  strength  of  the  interaction  with  zwitterionic  membranes  or  micelles  and  the 
mechanism of insertion, thus permitting to predict  models to design non-toxic peptides 
which still retain antimicrobial activity (Khandelia H. et al., 2006; Sayyed-Ahmad A. et al., 
2009; Mihajlovic M. and Lazaridis T., 2010).
The computational studies described above are all conducted in the presence of a micelle 
or a lipid bilayer with explicit solvation, except for the works by Mihajlovic M. and Lazaridis 
T., (2010) and He Y. et al., (2013), where instead simulations were run in implicit models of 
membrane and pores of different geometry. The use of implicit solvation simplify a fully 
atomistic simulation, reducing the number of atoms of the system, and the modelling of 
CAMPs in implicit solvations of different nature (polar  vs. non polar) could highlight their 
possible influence on the structure of the peptides.
1.4 Proteins as carrier of cryptic CAMPs
In  the last  years,  several  fragments possessing antimicrobial  activity were identified in 
many proteins, whose activity is often not correlated with immunity; some examples are 
given by human proteins like lysozyme (Ibrahim H. R. et al., 2005), thrombin (Kasetty G. et 
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al., 2011a), cathepsin G (Shafer W. M. et al., 1993), apolipoprotein E (Dobson C. B. et al., 
2006), RNase 3 (Boix E.  et al., 2012). These proteins seem to act as carrier of cryptic 
CAMPs, that  could be cut  and released by the action of endogenous and/or bacterial  
proteases; it can be hypothesized that evolution created proteins with hidden host-defense 
potential in their primary structure, besides “canonical” antimicrobial peptides encoded by 
genes (D'Alessio G., 2011). The cryptic antimicrobial peptides are often located at the N- 
or C-terminal of the protein, and thus the excision by proteases can be easily triggered 
(Kasetty G. et al., 2011b; Torrent M. et al., 2013) (Figure 6).
Figure 6:  3D-structure of human thrombin (PDB code: 1PPB) with the C-terminal antimicrobial 
region coloured in green (Kasetty G. et al., 2011a).
Moreover, a new link between the complement system and the antimicrobial peptides, the 
two main branches of the innate immune system, was established with the discovery of 
antimicrobial fragments of complement factors C3a (Nordahl E. A.  et al., 2004) and C8a 
(Zhang Z.  et al.,  2014),  while the identification of an antimicrobial  peptide released by 
fibrinogen suggests a new connection between immunity and blood coagulation (Påhlman 
L. I. et al., 2013). Other interesting examples of cryptic CAMPs stored inside proteins not 
correlated  with  immunity  are  instead  given  by  different  heparin-binding  domains 
(Andersson E.  et al., 2004) and by growth-factors (Malmstem M. et al., 2007). Following 
tissue damage and infection, the complement system and the coagulation cascade are 
activated, growth factors and antimicrobial peptides expression is enhanced and thus a 
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synergistic action of “canonical” and hidden CAMPs against pathogens can be imagined.
These particular antimicrobial peptides of human origin possess an high potential, since 
they  could  be  easily  used  as  therapeutic  molecules  due  to  the  “virtual”  absence  of 
immunogenicity.
1.5 State of the art in the field of cryptic CAMPs' discovery
The search  of  hidden  antimicrobial  peptides  is  often  conducted  in  a  random way,  by 
synthesizing a set of overlapping peptides which cover the entire amino acidic sequence of 
the protein of interest and testing their activity or by focusing instead on the analysis of the 
fragments generated by proteases. These experimental procedures can be expensive and 
time-consuming,  and  thus  faster  bioinformatic  approaches,  capable  of  highlighting  the 
presence of a putative antimicrobial region, could prove extremely useful. Several tools 
have already been developed and a brief review of them will be given in this paragraph. 
Torrent M. et al., (2009 and 2012) used an antimicrobial propensity scale of the different 
amino acids to screen protein sequences with a sliding window system; the scale was 
based on the study of the antimicrobial  activity of all  amino acid substitutions for each 
position of a 12-mer peptide, the bovine bactenicin 2A. This system was able to correctly 
identify the 80-90% of known antimicrobial domains and identified new domains previously 
uncharacterised in antimicrobial proteins. Brand G. D.  et al., (2012) developed Kamal, a 
software  that  uncover  putative  antimicrobial  sequences  from  proteins  based  on 
physicochemical  similarity  to  a  sample  of  known  antimicrobial  peptides.  Some  of  the 
physicochemical  properties  taken  into  account  are  net  charge,  isoelectric  point, 
hydrophobicity, hydropathy and the propensity to aggregation; several new antimicrobial 
fragments were identified in different organisms. PeptideLocator (Mooney C. et al., 2013) 
focus instead on the identification of a broad panel of bioactive peptides, which include 
also  CAMPs,  while  Niarchou  A.  et  al.,  (2013)  scanned  plant  proteins  for  putative 
antimicrobial  regions  using  a  machine  learning  approach  based  on  physicochemical 
descriptors of the amino acids and trained on a set of known CAMPs; sequences whose 
antimicrobial probability exceeded 90% were stored in a database.
It  has to be noticed that an arbitrary choice of physicochemical parameters taken into 
account can lead to a biased selection of putative antimicrobial peptides, that does not 
consider their extreme variation in nature; the method by Torrent M. et al., (2009 and 2012) 
could instead be biased by the choice of a single peptide for the study of the amino acids  
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substitutions.
1.6 Aims
The main aims of this research work are:
I. development  of  a  novel  bioinformatic  tool  allowing  the  identification  of putative 
antimicrobial peptides inside human proteins;
II. development and optimization of a novel system for the recombinant expression of 
newly identified CAMPs, followed by the biological and structural characterization of 
peptides;
III. modelling of CAMPs  by a Monte Carlo strategy with implicit solvents, in order to 
define the parameters which better reproduce the experimentally derived structures, 
thus paving  the  way to  the development  of  strategies  for  ab initio modelling of 
CAMPs.
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2. MATERIALS AND METHODS
BIOINFORMATIC SECTION
2.1 Development of the scoring system for the identification of hidden CAMPs
The “antimicrobial scores” of a peptide were calculated using the following formulas:
Relative score (RS) = (CmHn) / MaxScore
Absolute Score (AS) = RS x Ls
Where
- C is the net charge of the peptide calculated by the algebraic sum
# of Arg + # of Lys - # of Glu - # of Asp + 1 (if the N-terminus is a free amino group) - 1 (if  
the C-terminus is a carboxylic group).
- H is the arithmetical sum of the hydrophobicity scores of all the residues of the peptide 
(taken from the scales derived from HPLC retention times as described in the Results and 
Discussion section).
- L is the number of residues in the peptide.
- MaxScore (maximum score) is the highest (CmHn) value obtainable for a peptide at given 
values of the coefficients  m and  n. Maximum scores where obtained by calculating the 
scores of all the possible peptides composed exclusively by Arg residues and the residue 
with the highest hydrophobicity score in the chosen hydrophobicity scale (Ile, in the case of 
Cowan’s scales; Phe, in the case of Monera’s scales; Trp, for all the other hydrophobicity 
scales).
More in detail, indicating with #R the number of arginine residues in the peptide
0 ≤ #R ≤ L;
the number of hydrophobic residues, #H, will be exactly #H = L - #R;
the number of possible peptides will be L+1 (only the composition of the peptides and not 
their primary sequence is considered);
The absolute maximum of the product (CmHn) is obtained when C = m/(m + n) and H = n/
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(m + n), however, as the ratios m/(m + n) and n/(m + n) can assume non integer values 
and the charge C can, obviously, only be an integer (C = #R + 1, for a peptide with a free  
amino terminal group and an amidated C-terminus) the highest (CmHn) value for a peptide 
will be obtained when C is as close as possible to m/(m + n).
It should be noted that using hydrophobicity scales which do not assign a hydrophobicity 
score to arginine (see Results and Discussion section) the highest scoring peptide can 
indifferently  contain  arginine  or  lysine  residues,  whereas  using  hydrophobicity  scales 
which assign a hydrophobicity score to arginine, arginines-containing peptides will have 
higher scores than lysine containing peptides.
- Coefficients m and n are strain dependent variables that were calculated correlating RS 
or AS values and experimental potency data of a selected peptide set (described in the 
Results  and  Discussion  section)  on  a  defined  strain  through  the  use  of  the  linear 
regression  option  of  Microsoft  Excel.  Experimental  potency values  were  calculated  as 
Log(1000/Effective  Concentration)  where  the  “effective  concentration”  can  be  the half  
maximal inhibitory concentration (IC50) or the  minimum inhibitory concentration (MIC) i.e. 
the lowest concentration that inhibits the visible growth of the microorganism. RS or AS 
values were calculated setting to 1 the initial values of  m and  n and calculating the R2 
value, hence the m and n values were manually changed and R2 value re-calculated. By 
using this iterative procedure we defined the combination of m and n values providing the 
highest R2 value. Coefficients m and n were calculated using two peptide sets described 
by Fjell C. D.  et al., (2009), RANDOM200 and RANDOM19 peptide sets, (described in 
details in the Results and Discussion section). The sequences of the RANDOM19 peptide 
set are reported in table 1.
-  Coefficient  s is  a  strain  dependent  variable  that  describes  the  dependence  of  the 
antimicrobial  potency  from  the  length  of  antimicrobial  peptides.  It  was  calculated  by 
correlating  AS  values  and  the  experimental  potency  data  of  a  set  composed  by  ten 
peptides of similar composition but different length (Wiradharma N. et al., 2011) measured 
on Bacillus subtilis through the use of the linear regression option of Microsoft Excel. We 
used the same iterative procedure described for the determination of m and n values.
As defined, RS can assume all the values from 0 to 1, whereas AS can assume all the 
values from 0 to Ls.
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Table 1: primary structures of the RANDOM19 set from Fjell C. D. et al., (2009).
Primary structure
RLARIVVIRVAR
KIWWWWRKR
RWRRWKWWL
WRWWKIWKR
WKRWWKKWR
WKKWWKRRW
FRRWWKWFK
LRWWWIKRI
RKRLKWWIY
KKRWVWIRY
KWKIFRRWW
RKWIWRWFL
IWWKWRRWV
RRFKFIRWW
AVWKFVKRV
AWRFKNIRK
KRIMKLKMR
AIRRWRIRK
VVLKIVRRF
2.2 Validation of the scoring function
The validation of the scoring function was performed through the window analysis of a set  
of proteins with known antibacterial domains using the sets of exponents determined for 
Staphilococcus  aureus ATCC 25923  and  Pseudomonas  aurginosa H103,  the  “Parker” 
scale zeroed at glycine (see Results and Discussion section) and a window size from 12 to 
40 residues. The analysis was conducted using Microsoft Excel.
EXPERIMENTAL SECTION
2.3 Materials
Ampicillin,  bovine  serum  albumin  (purity  >  97%),  IPTG,  urea,  betaine,  DTT,  β-
mercaptoethanol, guanidine chloride, agar were purchased from  Sigma-Aldrich. Trypton 
was purcahsed from Applichem, yeast extract from Becton Dickinson. Sodium chloride and 
acrylamide (40% stock solution) were from Applichem.
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2.4 General procedures
Cell  transformation and Luria-Bertani medium preparation were performed according to 
Sambrook J. et al., (1989). SDS-PAGE was carried out according to Laemmli U. K. (1970). 
Protein concentrations were determined by  the method of Bradford, using BSA as the 
standard (Bradford M. M., 1976) and by UV spectroscopy using the theoretical, sequence-
based extinction coefficients in table 2 (Gill S. C. and von Hippel P. H.,1989).
Table 2: sequence-based extinction coefficients of the optimized fusion construct and ThrAP.
Extinction coefficient
(M-1 cm-1)
ONC-DCless-HIS-ThrAP 24410
ThrAP 8480
2.5 Preparation of the semi-defined rich medium (SDRM)
The novel liquid growth medium was prepared by dissolving in one litre of deionized water 
34 g of trypton, 12 mL of glycerol, 3 g of citric acid(1H2O), 2.31 g of KH2PO4, 12.54 g of 
K2HPO4, 4 g of glucose, 3 mL of NH3 25%, 1 mL of betaine 1 M and 5 mL of a solution of 
micro-nutrients with  the following composition expressed in g/L:  5.4 g of  MgO, 1 g of  
CaCO3, 0.72 g of ZnSO4(7H2O), 0.56 g of MnSO4(H2O), 0.125 g of CuSO4(5H2O), 0.14 g of 
CoSO4(7H20),  0.03  g  of  H3BO3, 25.6  mL of  HCl,  30.1  of  MgSO4 (0.25M),  2.25  g  of 
FeSO4(7H2O) (Fe2+16 mM), 2.502 g of FeSO4(7H2O), 0.004 g of NiCl2(6H2O), 0.006 g of 
Na2MoO4(2H2O). The pH of the medium was adjusted to 7.5 with NH3 25%.
2.6 Heterologous expression and preliminary purification of the fusion 
construct
Escherichia coli BL21(DE3) cells (AMS Biotechnology) were used for recombinant protein 
expression; cells transformed with pET 22b(+)-fusion construct were grown in 1 liter of 
SDRM containing ampicillin (0.1 mg/mL). When the culture reached an A 600 nm of 3 OD unit, 
protein expression was induced by the addition of 0.4 mM IPTG and the bacterial culture 
was grown over-night. Cells were harvested by centrifugation (6000 rpm, 4°C, 10', JA-14 
rotor, Beckman) and pellets were lysed by sonication in lysis buffer (0.1 M Tris-HCl, pH 
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7.4, containing 10 mM EDTA) at a final concentration of 100 OD/mL in an ultrasonic liquid 
processor (Misonix Ultrasonic Processor XL) with 30'' impulses, each followed by a 30'' 
rest, for a 30' total time, at 20 kHz. The suspension was then centrifuged at 12000 rpm for 
30' at 4°C (JA-25.50 rotor, Beckman). The inclusion bodies were freed from membrane 
proteins by three washes in 0.1 M Tris-HCl, pH 7.4, containing 10 mM EDTA, 2 % Triton X-
100 and 2 M urea, followed by repeated washes in 0.1 M Tris-HCl pH 7.4, containing 10 
mM EDTA,  to  eliminate  traces  of  Triton  and  urea.  This  procedure  eliminated  several  
contaminant  proteins  and cellular  debris  entrapped in  inclusion  body pellets.  Inclusion 
bodies of the fusion constructs without His●tag®  where dissolved in 0.1 M Tris-HCl pH 8, 
10 mM EDTA, 6 M GuHCl and 25 mM DTT at a final concentration of 10 mg/mL, purged 
with N2, and incubated at 37°C for 3 h. The protein solution was acidified to pH 5 with  
glacial acetic acid and extensively dialyzed against  0.1 M acetic acid (pH 3) at 4°C. Any 
insoluble material was removed by centrifugation (12000 rpm, 30', 4°C, rotor JA-25-50, 
Beckman). Inclusion bodies of the fusion constructs containing the His●tag® where purified 
with IMAC.
2.7 Immobilized metal-affinity chromatography (IMAC)
Inclusion bodies, following the preliminary washes, were dissolved in 50 mM Tris-HCl pH 
8, 6 M GuHCl and 20 mM β-mercaptoethanol (binding buffer) at a final concentration of 8-
10  mg/mL,  purged  with  N2,  and  incubated  at  37°C  for  3  h.  Denatured  and  reduced 
inclusion bodies were over-night incubated in batch at 4°C with the chromatographic resin 
Ni-NTA Agarose (Quiagen), previously equilibrated in the binding buffer, under continuous 
stirring. Following binding of the tagged protein, the resin was extensively washed in batch 
with 50 mM Tris-HCl pH 8, 6 M GuHCl and 10 mM β-mercaptoethanol (wash buffer), at  
4°C and under continuous stirring. The resin was finally packed into a column and the 
elution was performed by lowering the value of pH from 8 to 5 using sodium-acetate 0.1 M 
pH 5, 6 M GuHCl and 10 mM β-mercaptoethanol (elution buffer). The fractions of interest 
were  pooled  and  extensively  dialyzed  against  0.1  M  acetic  acid  (pH  3)  at  4°C.  Any 
insoluble material was removed by centrifugation (12000 rpm, 30', 4°C, rotor JA-25-50, 
Beckman) and through filtration with 0.2 μm filters (Corning).
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2.8 Self-cleavage of the fusion construct and isolation of the peptide
The solution containing the fusion construct was acidified to pH 2 with HCl, purged with N2, 
and incubated at 60°C for 24 h in a water bath. Following the cleavage, the solution was 
alkalized to pH 7-7.2 with the addition of NH3 1 M, purged with N2 after the addition of 2 
mM β-mercaptoethanol and over-night incubated at 28°C in a water bath. The peptide was 
isolated from the insoluble components through repeated cycles of centrifugation (12000 
rpm, 30',  4°C,  rotor  JA-25-50,  Beckman) and was finally lyophilized.  The purity of  the 
peptide was checked through SDS-PAGE and mass spectrometry.
2.9 Bactericidal assays
The bactericidal assays were conducted by D. Anna Zanfardino (Department of Biology, 
University Federico II). A single colony of the different bacterial strains was re-suspended 
in 5 mL of TSA medium (Becton Dickinson) and over-night incubated at 37°C and 150 rpm. 
When the culture reached an A 600 nm of 1 OD unit, it was diluted to 1:1000 in NaP 20 mM, 
pH 7.0 buffer. Samples with a finale volume of 1 mL were then prepared; the bacterial cells 
constituted the 4% of the volume, and the different proteins at various concentrations were  
added,  with  20  mM NaP,  pH 7.4  buffer  used  to  reach  the  final  volume.  The  positive 
controls were represented by cells incubated without protein  and with BSA at the same 
concentrations of the proteins tested, while instead the negative control was obtained by 
incubating the cells with ampicillin (0.05 mg/mL).  Samples were incubated at 37°C and 
150 rpm for 4 hours; serial dilutions (1:100, 1:1000) of all the samples were plated on solid  
TSA and the Petri dishes were over-night incubated at 37°C. The next day the amount of  
survived cells was estimated, by counting the number of colonies on each Petri dish and 
comparing it with the controls.
2.10 Circular dichroism measurements
Circular dichroism (CD) spectra were recorded with a Jasco J-715 spectropolarimeter at 
room  temperature.  The  molar  ellipticity  per  mean  residue,  [θ]  in  degrees  square 
centimeters per decimole, was calculated from the equation [θ]  = ([θ]obs  mrw)/(10  l C), 
where [θ]obs is  the ellipticity measured in degrees,  mrw is the mean residue molecular 
weight (124.2 for ThrAP and 125.68 for ApoE-AP), C is the peptide concentration in grams 
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per milliliter,  and  l is  the optical  path length of  the cell  in centimeters.  Cells with  path 
lengths of 0.1 cm were used and CD spectra were recorded with a time constant of 4 s, a  
2 nm bandwidth, and a scan rate of 20 nm/min; the signal was averaged over at least  
three scans and baseline corrected by subtraction of a buffer spectrum. Spectra were 
analyzed for secondary structure content using the PEPFIT tool (Reed J. and Reed T. A., 
1997). Peptide concentrations were typically 35-40 μM (or 10 μM where specified) in 10 
mM NaP pH 7.4 in the presence or absence of LPS and alginate, or in water with different  
concentrations of TFE or SDS 20 mM. Escherichia coli LPS 0111:B4 and seaweed alginate 
(Sigma Aldrich) were used at a final concentration of 0.2 mg/mL.
COMPUTATIONAL SECTION
2.11 Monte Carlo simulations
CAMPs  NMR  structures  were  downloaded  from  PDB  and  the  first  structure  of  each 
ensemble was chosen as starting conformation. The conformational space of peptides was 
explored  by  Monte  Carlo  (MC)  simulations  using  the  ZMM  software 
(http://www.zmmsoft.com/) and the AMBER force field (Weiner S. J.  et al., 1984). Initial 
structures were subjected to 10000 MC steps, each followed by 2000 iterations of energy 
minimization, at constant temperature (T = 300 K). Simulations were performed in vacuum, 
implicit water,  with the Effective Energy Function-1, EEF-1, (Lazaridis T. and Karplus M., 
1999), implicit octanol  (Hopfinger A. J. and Battershell R. D., 1976) and implicit octanol 
with  an attenuation of  solvation energy,  obtained through the modification  of  the  SEC 
(Solvation Energy Coefficient) parameter of ZMM. SEC values used for the analysis were 
1.0, 0.5 and 0.25 corresponding to full octanol solvation energy, one half and one fourth of  
the octanol  solvation energy,  respectively. In all  the calculations,  a distance-dependent 
dielectric  permeability  ε  =  4  x  r  and a cut  off  at  the  distance of  8  Ǻ for  non-bonded 
interactions were used.  Secondary  structure,  structural  alignments  and  ASAs  were 
analyzed using Swiss-PDBViewer; images were produced with the PyMol and Swiss-PDB 
Viewer.
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3. RESULTS AND DISCUSSION
BIOINFORMATIC SECTION
3.1 A novel scoring function for the identification of cryptic CAMPs
Several  researchers  have  attempted  to  develop  methods  to  predict  the  antimicrobial  
efficacy of CAMP or the presence of CAMP-like sequences inside the primary structure of 
(large) proteins that we call for simplicity “cryptic CAMPs”. All these methods include very 
large sets of properties (up to 23 molecular descriptors in a QSAR study Fjell C. D. et al., 
(2009))  and  sometime  arbitrary  chosen  properties,  like  tendency  to  form  amyloid 
structures: even if few well-known amyloid peptides have antimicrobial activity (Kagan B. 
L. et al., 2012), at the moment there is no indication that the ability to form amyloid fibrils is  
a general requirement. Moreover, all the cited studies ignore the fact that if a correlation 
does exist between sequence and/or structure of CAMPs and their antimicrobial activity,  
this  correlation  could  be  strain  specific.  Even  if  membranes  of  bacteria  share  some 
molecular features as a net negative charge on both sides of the membrane, each strain 
has  its  peculiar  composition:  the  abundance  of  the  negatively  charged  phospholipids 
(prevalently cardiolipin and phosphatidylglycerol) can vary from about 20% (e.g. in E. coli) 
to  almost  100%  (e.g.  in  Staphylococcus and  Streptococcus).  Furthermore,  even  the 
proportion of cardiolipin and phosphatidylglycerol varies from strain to strain (Epand R. M. 
and Epand R. F., 2009).
In order to derive a set of functions able to predict the antimicrobial activity of peptides on 
specific strains, we started from the molecular model of a crucial step common to all the 
models of antimicrobial activity (Figure 7): the CAMP adopts an amphipathic structure and 
inserts into the membrane, parallel to the membrane surface. Two major forces stabilize 
this  complex:  the electrostatic interaction between anionic  phospholipids and positively 
charged residues on the peptide and the hydrophobic interaction between hydrophobic 
residues of the peptide and the fatty acid chain of phospholipids. It  is  well-known that 
anionic phospholipids encircle the CAMP, a phenomenon known as “phase separation”, 
therefore, the interaction CAMP/membrane, from the electrostatic point of view, resembles 
the interaction between a poly-anion and a poly-cation. Assuming that the electrostatic and 
the hydrophobic components act synergistically to increase the stability of the complex and 
that antimicrobial activity increases proportionally to the stability of the complex, then, the 
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antimicrobial activity of a CAMP should be proportional to the product:
CmHn
where, C is a measure of the electrostatic attraction (e.g net charge of the CAMP), H is a  
measure of the hydrophobic interaction contribution and exponents m and n determine the 
relative contribution of the two forces to the stability of the complex CAMP/membrane. We 
want to underline that the exponents  m and  n,  likely,  are not “universal” and could be 
unique for each strain depending on the relative abundance of negatively charged lipids 
but also on other peculiarities of bacterial strains like, for example, the properties of the  
fatty acids (length, double bonds, ramifications, cyclopropane rings, etc.).
Figure 7: representation of the universal model of interaction between a CAMP and the bacterial 
membrane.
The product CmHn is particularly well suited to describe any possible relative contribution of 
charge and hydrophobicity. Figure 8 (A and B) shows the dependence of the CmHn product 
from exponents m and n for a set of model 10 aa long peptides composed only by arginine 
and tryptophan. For each peptide, C was calculated as the sum of the number of arginine 
residues  (therefore,  C  is  the  net  charge  of  the  peptides),  whereas  H  was  calculated 
assigning  arbitrarily  a  “hydrophobicity  score  =  1”  to  each  tryptophan residues  and 
considering additive the contributions of tryptophan residues (therefore, H the sum of the 
number of  tryptophan residues). The arbitrariness of the choice is compensated by the 
exponents, in fact, if the exponents are identical then the highest scoring peptides are the  
peptides  with  five  arginines  and  five  tryptophan residues,  whereas,  if  n>m, then  the 
highest scoring peptides are the peptides with more  tryptophan residues than arginine 
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residues  and  vice  versa.  For  example  if  m=0.6  and  n=1.4,  then  the  highest  scoring 
peptides have seven tryptophan and five arginine residues respectively. It should be noted 
that the percentage of tryptophan residues in the highest scoring peptides is simply given 
by the ratio n/(m+n). Moreover, at a fixed ratio n/m, the increase in the sum m+n causes 
an increase in the steepness of the score curve, i.e. the relative score of the non-optimal 
peptides decreases (compare the black, red and blue curves in figure 8).
Figure 8: dependence of the CmHn product (relative score) from exponents  m and n for a set of 
model 10 aa long peptides composed only by arginine and tryptophan.
Our calculation contains another arbitrary assumption: independently from the sequence, 
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all the arginine and tryptophan residues provides the same contribution. This is equivalent 
to  assuming  that  each  peptide,  independently  from the  sequence,  adopts  a  perfectly 
amphipathic  conformation  with  all  the  tryptophan  and  arginine  residues  oriented  in  a 
productive  way to  contribute  to  the  binding.  This  assumption  is  not  unlikely  for  short 
peptides which are notoriously flexible but will not be true for peptides long enough to have 
a  specific  folding  or  for  disulphide-rich  peptides,  whose  folding  is  constrained  by  the 
disulphides.
In our simple example we have assigned a hydrophobicity score = 1 to tryptophan. More 
generally, it is necessary to derive a relative score of hydrophobicity for all the residue 
which are supposed to be placed on the hydrophobic side of the CAMP bound to the 
membrane. An impressive number of hydrophobicity scale have been published, however,  
as we need to score the ability of a side-chain inserted into a peptide framework to interact  
with the fatty acid chains of phospholipids, we have selected few scales (Table 3) derived 
by measuring retention times on C18 HPLC columns at pH 7 (in phosphate buffer) of free 
amino-acids or specific peptide libraries (Table 4). These scales, usually derived to predict  
the retention times of peptides in HPLC, are particularly well suited to estimate the relative 
contribution to membrane binding of hydrophobic amino-acids.
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Table 3: hydrophobicity scales normalized between 0 and 1.
Cowan Kovacs(a)a Kovacs(b)a Parker Monera AVE2b AVE3c
Trp 0.879 1.000 1.000 1.000 0.983 1.000 1.000
Phe 0.965 0.916 0.931 0.959 1.000 0.962 0.969
Leu 0.992 0.76 0.792 0.959 0.983 0.976 0.916
Ile 1.000 0.707 0.74 0.902 0.990 0.950 0.882
Met 0.817 0.551 0.59 0.711 0.833 0.763 0.715
Val 0.872 0.486 0.538 0.686 0.843 0.778 0.693
Tyr 0.460 0.514 0.549 0.597 0.760 0.616 0.639
Cys 0.731 0.318 0.382 0.432 0.670 0.580 0.497
Pro 0.751 0.355 0.422 0.397 0.173 0.573 0.333
Ala 0.628 0.174 0.266 0.397 0.620 0.512 0.430
His 0.377 0.190 0.266 0.397 0.403 0.386 0.357
Arg 0.163 0.174 0.338 0.289 0.263 0.227 0.298
Thr 0.472 0.174 0.243 0.241 0.437 0.356 0.309
Gln 0.307 0.103 0.182 0.216 0.290 0.253 0.231
Lys 0.153 0.000 0.266 0.200 0.207 0.184 0.225
Gly 0.540 0.056 0.182 0.200 0.357 0.378 0.248
Ser 0.382 0.090 0.171 0.175 0.323 0.278 0.224
Asn 0.291 0.084 0.165 0.149 0.173 0.221 0.163
Glu 0.050 0.044 0.012 0.108 0.157 0.080 0.093
Asp 0.000 0.034 0.000 0.000 0.000 0.000 0.000
a the  two  scales  were  derived  using  the  same set  of  peptides  and  the  same experimental  conditions  
(phosphate buffer pH 7.0) except that in the case of the Kovacs(b) scale 0.1 M NaClO4 was added to the 
buffer (Kovacs J. M. et al., 2006).
b this scale is an average of the scales of Cowan (Cowan R. and Whittaker R. G., 1990) and Parker (Parker 
J. M. R. et al., 1986). Trp value was arbitrarily set to 1.
c this scale is an average of the scales of Kovacs(b), Parker and Monera (Monera O. D. et al., 2005). The 
scales of Parker and Monera, like the scale Kovacs(b), were obtained with buffers containing NaClO4.
Table 4: peptide sets used to derive the hydrophobicity scales.
Scale Peptide librarya notes
Cowan NH2-X-COOH amino-acids
Kovacs Ac–XGAKGAGVGL–amide random coil peptides
Parker Ac–GXXLLLKK–amide random coil peptides
Monera Ac–EAEKAAKEXEKAAKEAEK–amide helical peptides
a X denotes any of the twenty canonical amino-acids.
The scale described by Monera et al. was derived using an helical peptide and is strongly 
influenced by structural effects, for example proline, an helix-breaking residue, in this scale 
is a very hydrophilic residues. The scales of Kovacs, on the other hand, are influenced by 
the very high solvent exposure of the variable residue. The scale of Parker is intermediate,  
presenting  two  adjacent  copies  of  the  variable  residue,  one  more  exposed  at  the  N-
terminus of the peptide and one packed between the preceding residue and a leucine 
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residue. Not surprisingly, a scale obtained by averaging the previous three scales is very 
similar to the scale of Parker and co-workers. Finally, the scale of Cowan, being based on 
the retention times of free amino-acids, shows some peculiarities as the fact that aliphatic  
residues isoleucine and leucine are the most  hydrophobic and proline and glycine are 
much more hydrophobic than in the other scales. We have also prepared an average scale 
between the scales of Cowan and Parker.
It should be remembered that, according to our model, the H value in the product CmHn is 
the sum of the hydrophobic contribution of the residues located on the hydrophobic face of 
the  CAMP.  Therefore,  the  scales  in  table  3  are  just  the  starting  point  to  derive  the 
hydrophobicity scores of the residues that will be frequently located on the hydrophobic 
face of  the CAMP, thus contributing  to  the binding.  As a score  = 0 can be arbitrarily 
assigned to different residues, each scale can give rise to more than one score list as  
shown in tables 4 A-G.
Table 4-A: hydrophobicity scales derived from the Cowan’s scale
Cowan Cowan-Ser0 Cowan-Gly0
Ile 1.000 1.000 1.000
Leu 0.992 0.988 0.984
Phe 0.965 0.943 0.923
Trp 0.879 0.805 0.738
Val 0.872 0.793 0.721
Met 0.817 0.703 0.601
Pro 0.751 0.598 0.459
Cys 0.731 0.565 0.415
Tyr 0.638 0.415 0.213
Ala 0.628 0.398 0.191
Gly 0.540 0.256 0
Thr 0.472 0.146 0
Ser 0.382 0 0
His 0.377 0 0
Gln 0.307 0 0
Asn 0.291 0 0
Arg 0.163 0 0
Lys 0.153 0 0
Glu 0.050 0 0
Asp 0.000 0 0
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Table 4 B: hydrophobicity scales derived from the Parker’s scale.
Parker Parker-Ser0 Parker-Gly0 Parker-Arg0
Trp 1.000 1.000 1.000 1.000 
Leu 0.959 0.952 0.949 0.944 
Phe 0.959 0.952 0.949 0.944 
Ile 0.902 0.879 0.873 0.859 
Met 0.711 0.648 0.631 0.592 
Val 0.686 0.618 0.599 0.556 
Tyr 0.597 0.509 0.484 0.430 
Cys 0.432 0.309 0.274 0.197 
Ala 0.397 0.267 0.229 0.148 
Pro 0.397 0.267 0.229 0.148 
His 0.397 0.267 0.229 0.148 
Arg 0.289 0.139 0.096 0 
Thr 0.241 0.079 0.032 0
Gly 0.216 0.048 0 0
Lys 0.200 0.048 0 0
Gln 0.200 0.030 0 0
Ser 0.175 0 0 0
Asn 0.149 0 0 0
Glu 0.108 0 0 0
Asp 0 0 0 0
Table 4-C: hydrophobicity scales derived from the Kovacs’s scale (a).
Kovacs(a) Kovacs(a)-Glu0 Kovacs(a)-Gln0 Kovacs(a)-Arg0
Trp 1.000 1.000 1.000 1.000 
Phe 0.916 0.912 0.906 0.898 
Leu 0.760 0.749 0.733 0.709 
Ile 0.707 0.694 0.674 0.645 
Met 0.551 0.531 0.500 0.457 
Tyr 0.514 0.492 0.458 0.411 
Val 0.486 0.463 0.427 0.377 
Pro 0.355 0.326 0.281 0.219 
Cys 0.318 0.287 0.240 0.174 
His 0.190 0.153 0.097 0.019 
Ala 0.174 0.137 0.080 0
Thr 0.174 0.137 0.080 0 
Arg 0.174 0.137 0.080 0 
Gln 0.103 0.062 0 0 
Ser 0.090 0.049 0 0 
Asn 0.084 0.042 0 0 
Gly 0.056 0.013 0 0 
Glu 0.044 0 0 0 
Asp 0.034 0 0 0 
Lys 0 0 0 0
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Table 4-D: hydrophobicity scales derived from the Kovacs’s scale (b).
Kovacs(b) Kovacs(b)-Ser0 Kovacs(b)-Gln0
Trp 1.000 1.000 1.000 
Phe 0.931 0.916 0.915 
Leu 0.792 0.749 0.746 
Ile 0.740 0.686 0.682 
Met 0.590 0.505 0.498 
Tyr 0.549 0.456 0.449 
Val 0.538 0.443 0.435 
Pro 0.422 0.303 0.293 
Cys 0.382 0.254 0.244 
Arg 0.338 0.202 0.191 
Lys 0.266 0.115 0.102 
Ala 0.266 0.115 0.102 
His 0.266 0.115 0.102 
Thr 0.243 0.087 0.074 
Gln 0.182 0.014 0 
Gly 0.182 0.014 0 
Ser 0.171 0 0
Asn 0.165 0 0
Glu 0.012 0 0
Asp 0 0 0
Table 4-E: hydrophobicity scales derived from the Monera’s scale.
Monera Monera-Ser0 Monera-Gln0
Phe 1.000 1.000 1.000 
Ile 0.990 0.985 0.984 
Trp 0.983 0.975 0.974 
Leu 0.983 0.975 0.974 
Val 0.843 0.769 0.757 
Met 0.833 0.754 0.741 
Tyr 0.760 0.645 0.627 
Cys 0.670 0.512 0.487 
Ala 0.620 0.439 0.409 
Thr 0.437 0.168 0.125 
His 0.403 0.118 0.073 
Gly 0.357 0.050 0 
Ser 0.323 0 0
Gln 0.290 0 0
Arg 0.263 0 0
Lys 0.207 0 0
Pro 0.173 0 0
Asn 0.173 0 0
Glu 0.157 0 0
Asp 0 0 0
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Table 4-F: hydrophobicity scales derived from the scale “average 2”.
AVE2 AVE2-Ser0 AVE2-Gly0
Trp 1.000 1.000 1.000
Leu 0.976 0.967 0.962
Phe 0.962 0.948 0.940
Ile 0.950 0.931 0.920
Val 0.778 0.693 0.644
Met 0.763 0.672 0.620
Pro 0.573 0.408 0.314
Cys 0.581 0.419 0.326
Tyr 0.617 0.469 0.384
Ala 0.512 0.323 0.215
Gly 0.378 0.137 0
His 0.386 0.149 0
Thr 0.356 0.108 0
Ser 0.278 0 0
Gln 0.253 0 0
Asn 0.221 0 0
Arg 0.227 0 0
Lys 0.184 0 0
Glu 0.080 0 0
Asp 0 0 0
Table 4-G: hydrophobicity scales derived from the scale “average 3”.
AVE3 AVE3-Gln0 AVE3-Gly0 AVE3-Arg0
Trp 1.000 1.000 1.000 1.000 
Phe 0.969 0.960 0.959 0.956 
Leu 0.916 0.891 0.888 0.880 
Ile 0.882 0.847 0.843 0.832 
Met 0.715 0.629 0.621 0.594 
Val 0.693 0.601 0.592 563
Tyr 0.639 0.531 0.520 0.486 
Cys 0.497 0.346 0.331 0.283 
Ala 0.430 0.259 0.242 0.188 
His 0.357 0.164 0.145 0.084 
Pro 0.333 0.133 0.113 0.050 
Thr 0.309 0.101 0.081 0.016 
Arg 0.298 0.087 0.066 0
Gly 0.248 0.022 0 0
Gln 0.231 0 0 0
Lys 0.225 0 0 0
Ser 0.224 0 0 0
Asn 0.163 0 0 0
Glu 0.093 0 0 0
Asp 0 0 0 0
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As for  the  determination  of  the  exponents  m and  n,  these values are  not  only strain 
dependent, as already discussed above, but also condition dependent. In fact, the ionic 
strength at  which  the antimicrobial  activity is  assayed could influence the electrostatic 
component of the CAMP/membrane interaction and hence the relative contribution of the 
ionic and hydrophobic components. Therefore, the sole way to determine the values of the 
two exponents is to analyze the antimicrobial activity values of a set of peptides with very 
different  composition  (i.e.  different  ratios  between  hydrophobic  and  basic  residues) 
determined using not only the same strain, but exactly the same assay. Fjell C. D. et al., 
(2009) published the antimicrobial activity on Pseudomonas aeruginosa H103 (measured 
as IC50 by an assay based on luciferase) of a set of 200 peptides 9 aa long of (almost) 
random composition. Even if some amino-acids are not present (e.g. Asp, Glu, Pro, Cys) 
and  other  are  underrepresented  (e.g.  Thr,  His,  Tyr)  this  set,  that  we  will  call  the 
RANDOM200 set, provides the opportunity to verify if antimicrobial activity is correlated to 
the product CmHn.
The graph in figure 9 shows the relative scores (RS) of the RANDOM200 set as function 
of the  antimicrobial potency.  Antimicrobial  potency was expressed as Log(1000/IC50), 
whereas the relative scores were calculated by the equation:
RS = (CmHn) / MaxScore                       (1)
where MaxScore is the highest score that a peptide can obtain at given m and n values 
and, hence, corresponds to the score of the “optimal” CAMP.
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Figure 9: linear correlation between the relative scores and the antibacterial potency of the 200 
peptides of the RANDOM200 set (Parker-Gly0 scale).
The  m and  n values shown in the graph were obtained setting the initial values of both 
exponents to 1 and then progressively changing them to find the values that maximise the 
R2 value of the least squares line. As no systematic exploration was performed, we cannot 
exclude that we found m and n values corresponding to a local maximum, nonetheless the 
correlation between our  RS and the experimental  antimicrobial  potency values is  very 
good. All the hydrophobicity scales of tables 4 A-G performed almost equally well, with the 
not surprising exception of the Cowan’s scale. The R2, m and n values are summarized in 
table 5.
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Table 5: values of the exponents m and n obtained through the linear fit with the RANDOM200 set.
Scale R2 m n fHa
Kovacs(a)-Arg0 0.833 1.30 1.30 0.50
Kovacs(a)-Gln0 0.825 1.33 1.50 0.53
Kovacs(a)-Glu0 0.816 1.32 1.60 0.55
Kovacs(b)-Gln0 0.813 1.30 2.00 0.61
Kovacs(b)-Ser0 0.814 0.92 1.52 0.62
Parker-Arg0 0.824 1.85 1.90 0.51
Parker-Gly0 0.812 1.88 2.14 0.53
Parker-Ser0 0.809 1.86 2.34 0.56
Monera-Gln0 0.806 2.88 2.88 0.50
Monera-Ser0 0.806 2.88 3.00 0.51
AVE2-Gly0 0.810 2.25 2.30 0.51
AVE2-Ser0 0.814 2.35 2.36 0.50
AVE3-Arg0 0.829 2.00 2.00 0.50
AVE3-Gly0 0.821 1.98 2.15 0.52
AVE3-Gln0 0.818 1.98 2.21 0.53
Cowan-Gly0 0.634 1.60 1.60 0.50
Cowan-Ser0 0.656 2.35 2.30 0.49
a fH, the ratio n/(n+m), is the fraction of hydrophobic residues in the highest scoring peptides.
All  the  peptides  of  the  RANDOM200  set  have  the  same  length,  allowing  an  easy 
comparison of their score and potency.  Wiradharma N.  et al., (2011) have characterized 
another smaller set of peptides with molecular features complementary to those of the 
RANDOM200 set. Their set is composed by peptides of very similar composition but of  
different lengths of general sequence (XXYY)n where n is 2, 3 or 4, X is Phe, Leu, Ala and 
Y is Arg or Lys.
The graph in figure 10 shows the absolute scores (AS) of the peptides as function of their 
antimicrobial potency. Antimicrobial potency was expressed as Log(1000/MIC), whereas 
the absolute scores were calculated by the equation:
AS = RS x Ls                       (2)
With all the hydrophobicity scales the best correlation was obtained with s = 1. Using the 
Parker-Arg0 or the AVE2-Ser0 scales we obtained R2 = 0.85 with the complete set of ten 
peptides and R2 = 0.95 by omitting the peptide (LLKK)2 whose activity is slightly lower than 
that predicted by equation 2.
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Figure 10:  linear correlation between the absolute scores and the antimicrobial potency of the 
(XXYY)n  peptides.  In  yellow:  (XXYY)3 peptides;  in  red:  (XXYY)2 peptides,  in  green:  (XXYY)4 
peptides (Parker-Arg0 scale).
These results clearly indicate that,  in a pool  of  peptides of similar composition (hence 
similar RS), the antimicrobial potency increases linearly with the length of the peptides (at  
least up to about 16 residues).
Using equation 2 in the simplified form:
AS = RS x L                      (3)
we have analyzed a second data set reported by Fjell and co-workers. This set, hereafter 
called RANDOM19, is composed by 18 representative peptides from the RANDOM200 set 
and  bactenicin  2A (Bac2A),  a  natural  CAMP 12  residues  long.  Fjell  and  co-workers 
measured the MIC values of the 19 peptides on twenty strains, including seven strains of  
P. aeruginosa, two of  Staphilococcus aureus,  two of Escherichia  coli etc;  interestingly, 
some of the strain are clinical isolates. For almost all the strains examined we found a very 
good linear correlation between the absolute scores calculated by equation 3 and the 
experimental potency, Log(1000/MIC). Figure 11 (A and B) and tables 6-ABC show some 
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representative results.
Figure 11:  linear correlation between the absolute scores and the antimicrobial potency of the 
RANDOM19 peptides  against  Staphilococcus  aureus ATCC  25923  (A)  and  Pseudomonas 
aeruginosa H103 (B) (Parker-Gly0 scale).
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Table 6-A: values of the exponents obtained for three strains of Pseudomonas aeuruginosa.
P. aer. H103 P. aer. Brazil 9 P. aer. LES400
m n fHa R2 m n fHa R2 m n fHa R2
Parker-Ser0 0.97 1.62 0.63 0.856 1.76 2.62 0.60 0.849 1.10 1.94 0.64 0.803
Parker-Gly0 0.96 1.45 0.60 0.860 1.64 2.22 0.58 0.851 1.00 1.62 0.62 0.804
Parker-Arg0 0.73 1.04 0.59 0.860 1.53 2.02 0.57 0.848 0.87 1.32 0.60 0.802
Kovacs(a)-Glu0 0.47 0.99 0.68 0.906 0.80 1.44 0.64 0.878 0.52 1.23 0.70 0.851
Kovacs(a)-Gln0 0.38 0.81 0.68 0.904 0.67 1.20 0.64 0.875 0.42 0.99 0.70 0.847
Kovacs(a)-Arg0 0.29 0.60 0.67 0.895 0.50 0.86 0.63 0.866 0.34 0.88 0.72 0.835
AVE2-Ser0 1.36 1.71 0.56 0.834 3.20 3.76 0.54 0.822 1.73 2.30 0.57 0.774
AVE3-Gln0 0.86 1.30 0.60 0.881 2.04 2.86 0.58 0.866 1.20 1.94 0.62 0.825
AVE3-Gly0 0.86 1.30 0.60 0.883 2.03 2.81 0.58 0.866 1.00 1.62 0.62 0.825
AVE3-Arg0 0.73 1.05 0.59 0.880 1.57 2.13 0.58 0.860 0.87 1.35 0.61 0.820
a fH, the ratio n/(n+m), is the fraction of hydrophobic residues in the highest scoring peptides.
Table 6-B: values of the exponents obtained for two strains of S. aureus and Escherichia coli.
S. aureus ATCC 
25923 S. aureus C623 E. coli 63103
m n fHa R2 m n fHa R2 m n fHa R2
Parker-Ser0 0.92 1.18 0.56 0.838 0.90 1.20 0.57 0.862 0.65 1.03 0.61 0.722
Parker-Gly0 0.92 1.07 0.54 0.841 0.88 1.07 0.55 0.864 0.65 0.93 0.59 0.723
Parker-Arg0 0.73 0.79 0.52 0.846 0.72 0.83 0.53 0.862 0.55 0.75 0.58 0.713
Kovacs(a)-
Glu0 0.55 0.75 0.58 0.906 0.51 0.75 0.60 0.862 0.36 0.69 0.66 0.745
Kovacs(a)-
Gln0 0.48 0.63 0.57 0.907 0.44 0.62 0.58 0.914 0.31 0.59 0.66 0.738
Kovacs(a)-
Arg0 0.41 0.49 0.54 0.901 0.37 0.50 0.57 0.902 0.25 0.46 0.65 0.724
AVE2-Ser0 1.16 1.20 0.51 0.812 1.12 1.20 0.52 0.834 0.85 1.02 0.55 0.680
AVE3-Gln0 0.91 1.06 0.54 0.863 0.86 1.06 0.55 0.882 0.64 0.93 0.59 0.729
AVE3-Gly0 0.85 0.98 0.54 0.866 0.80 0.97 0.55 0.882 0.62 0.88 0.59 0.727
AVE3-Arg0 0.75 0.82 0.52 0.867 0.72 0.83 0.54 0.878 0.55 0.75 0.58 0.718
a fH, the ratio n/(n+m), is the fraction of hydrophobic residues in the highest scoring peptides.
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Table 6-C: values of the exponents obtained for Klebsiella pneumoniae, Enterococcus faecium and 
Enterococcus faecalis.
K. pneumonie 
63575
E. faecium 
t62764 E. faecalis f43559
m n fHa R2 m n fHa R2 m n fHa R2
Parker-Ser0 1.50 3.40 0.69 0.715 0.51 0.81 0.61 0.790 0.04 1.00 0.96 0.756
Parker-Gly0 1.50 3.10 0.67 0.714 0.43 0.60 0.58 0.775 0.05 0.95 0.95 0.754
Parker-Arg0 1.50 3.10 0.67 0.716 0.43 0.60 0.58 0.759 0.00 0.68 1.00 0.730
Kovacs(a)-
Glu0 0.80 3.60 0.82 0.770 0.28 0.55 0.66 0.803 0.01 0.57 0.98 0.711
Kovacs(a)-
Gln0 0.74 3.80 0.84 0.771 0.24 0.46 0.65 0.788 0.00 0.50 1.00 0.689
Kovacs(a)-
Arg0 0.74 4.00 0.84 0.767 0.20 0.37 0.65 0.758 0.00 0.35 1.00 0.658
AVE2-Ser0 1.81 2.25 0.55 0.697 0.73 0.88 0.55 0.755 0.16 1.31 0.89 0.719
AVE3-Gln0 1.55 3.40 0.69 0.722 0.50 0.73 0.59 0.793 0.05 0.92 0.95 0.746
AVE3-Gly0 1.55 3.40 0.69 0.723 0.49 0.71 0.59 0.787 0.02 0.87 0.98 0.740
AVE3-Arg0 1.55 3.50 0.69 0.722 0.43 0.60 0.58 762 0.00 0.68 1.00 0.721
a fH, the ratio n/(n+m), is the fraction of hydrophobic residues in the highest scoring peptides.
Among the different hydrophobicity scales, the worst R2 values were obtained with the 
AVE2-Ser0 scale. Using the scales derived from Kovacs’ scale we obtained the highest R 2 
values, but  m and n values significantly lower than those obtained with the other scales. 
However, we noticed that, increasing proportionally both n and m, the R2 values obtained 
with  these scales decreased very slightly so that  for  n and  m values similar  to  those 
obtained with the other scales also the R2 values were similar. In other words, using the 
scales derived from Kovacs’ scale only the ratio between n and m is well defined, whereas 
their  absolute values cannot  be determined accurately.  It  should be noted that  all  the 
scales provide very similar  fH values for the same strain, but these values are different 
from strain to strain (Table 7)
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Table 7: average fH calculated from the different values obtained with the hydrophobicity scales.
Strain average fH SDa
P. aer. H103 0.62 0.043
P. aer. Braz9 0.59 0.034
P. aer. LES400 0.64 0.051
S. aureus ATCC 25923 0.54 0.022
S. aureus C623 0.56 0.025
E. coli 63103 0.60 0.038
K. pneumonie 63575 0.72 0.091
E. faecium t62764 0.61 0.038
E. faecalis f43559 0.97 0.035
a standard deviation.
3.2 In silico validation of the scoring function
Equation 3 is not only an effective tool to analyse the sensitivity to CAMPs of strains of  
interest, but also a very simple tool for the identification of new “cryptic” CAMPs. In fact, a 
protein sequence can be divided in all the possible peptides of a desired length and the 
absolute scores of these peptides can be reported in a graph as function of the position.  
As the absolute score increases linearly with the antimicrobial potency, the analysis not 
only  allows  to  determine  the  position  of  the  CAMP inside  the  precursor,  but  also  to 
estimate the MIC of the peptides, at least for the strains described above.
We verified the reliability of this approach by analysing two pools of sequences containing 
known CAMPs:
I. proteins containing known “cryptic” CAMPs;
II. cathelicidins, protegrins, α-defensins, and some other antimicrobial peptides which 
are  secreted  as  large  precursors  successively  cleaved  to  release  the  mature 
peptide  (from this  point  of  view several  traditional  CAMPs could  be considered 
“cryptic”  CAMPs,  the  only  difference  being  the  fact  that  the  propeptide  has  no 
function besides the secretion of the CAMP).
The first  group is very heterogeneous and contains CAMPs identified by a variegated 
panel  of  experimental  and  theoretical  approaches.  For  example,  some  CAMPs  were 
isolated by synthesizing overlapping peptides which covered the entire  sequence or a 
specific  region  of  the  protein  of  interest.  It  should  be noted that,  in  these  cases,  the 
location  of  the  CAMPs  within  the  sequence  of  their  precursors  is  known  with  good 
precision. In other cases the CAMPs were identified by fragmentation of the precursor with 
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different chemical or enzymatic strategies and, hence, the “optimal” peptide is not known.
Several  CAMPs  were  identified  by  homology  or  by  the  recognition  of  “consensus 
sequences”. For example, as the N-terminus of human RNase 3 (also known as eosinophil 
cationic protein) is a known antimicrobial peptide, some research groups systematically 
analysed the corresponding region in all the homologous RNases. Other groups analysed 
the  antimicrobial  activity  of  heparin-binding  sequences or  the  consensus sequence  X-
[PFY]-X-[AFILV]-[AFY]-[AITV]-X-[ILV]-X(5)-W-[IL]-X found in serine proteases.
For  the  analysis,  we  used the  parameters  reported  in  tables  6-ABC.  For  the  sake of 
brevity, we will discuss only the results obtained using the sets of exponents determined 
for  Staphilococcus aureus ATCC 25923 and  Pseudomonas aeruginosa H103, using the 
Parker-Gly0 scale. Table 8 shows the correspondence between absolute score values and 
MIC values for these two strains. These values are reported in graphs of figure 12 as 
thresholds for  the identification of  potential  CAMPs. In  each case the peak above the 
thresholds corresponds exactly to the known CAMP.
Table 8:  correspondence between absolute score values and MIC values for  the two selected 
strains.
Strain Absolute Scores
MIC: 100 μM MIC: 50 μM MIC: 10 μM MIC: 1 μM
Staphilococcus aureus 
ATCC 25923
6.33 6.73 7.64 8.95
Pseudomonas 
aurginosa H103
5.95 6.46 7.64 9.33
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Figure 12: window analysis of human LL-37 and FALL-39 precursor, human thrombin and bovine 
lactotransferrin, with the following window lengths, chosen according to the length of the known 
antimicrobial fragments: 39 aa. (blue), 37 aa (red), 25 aa. (grey) and 19 aa. (green). The arrows 
indicate known cryptic CAMPs described in literature, localized by the scoring function.
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Tables 9 A-F report for each analysed protein the position and the score of the highest 
scoring peptide and of selected peptides corresponding to local maxima of the absolute 
score profile.
Table 9-A: cryptic CAMPs identified by overlapping peptides.
Protein
(UniProt ID) Organism
Known 
cryptic 
CAMP/s 
(ref.)
Absolute 
maximum
S. aureus 
ATCC 
25923 
(score)
Local 
maxima S. 
aureus 
ATCC 
25923 
(score)
Score of 
known 
CAMPs S. 
aureus 
ATCC 
25923
Absolute 
maximum
P. aer.  
H103 
(score)
Relative 
maxima 
P. aer. 
H103 
(score)
Score 
of 
known 
CAMPs 
P. aer. 
H103
Prothrombin 
(P00734) Homo sapiens
598-617 
(a)
422-456* 
(8)
422-453* 
(6.7)
599-617 
(7.6)
7.3 599-617 (6.3)
422-453* 
(6.1) 5.9
Cathepsin G 
(P08311) Homo sapiens
81-100; 
127-156; 
218-243 
(b)
92-131 
(9.7)
89-122 
(8.5)
92-120 
(7.6)
214-248 
(6)
2.7; 4.3; 
3.7
92-131 
(7.0)
89-122 
(6.1)
92-120 
(5.5)
214-248 
(4.5)
1.7; 2.9; 
2.6
Heparin-cofactor 2 
(P05546) Homo sapiens
119-144 
(c)
202-241* 
(11.8)
113-142 
(10.1) 116-
142 (9.4) 
201-234* 
(10.1)
6.7 202-241* (9.4)
113-142 
(8.4) 
116-142 
(7.8) 
201-234* 
(8.3)
5.1
Complement C3 
(P01024) Homo sapiens
675-695; 
690-715; 
716-742; 
728-748 
(d)
471-508* 
(9.8)
678-716 
(6.5) 704-
740 (6.9)
2.4; 4.3; 
3.8; 2.4; 
3.2
471-508* 
(6.2)
678-716 
(4.3) 
704-740 
(4.9)
1.5; 2.5; 
1.6; 2.2
Thimic stromal 
lymphopoietin 
(Q969D9)
Homo sapiens 124-158 (e)
124-157, 
123-157, 
118-157 
(10.9)
/ 10.7 124-157, 123-157 (8) / 7.7
Kininogen-1 
(P01042) Homo sapiens
294-319; 
497-516 
(f)
362-393* 
(7.4)
297-324 
(7) 295-
324 (6.8)
6.3; 1.5 362-393* (5.5)
297-324 
(5.4) 
295-324 
(5.2)
4.7; 0.6
Tissue factor 
pathway inhibitor 
(P10646)
Homo sapiens 278-304 (g)
264-302, 
263-302 
(13)
264-296 
(12.3) 274-
302 (9.1)
7.6
264-302, 
263-302 
(9.6)
263-296 
(9.1) 
274-304 
(6.7)
5.5
References: (a) Kasetty G. et al., 2011a, (b) Shafer W. M. et al., 1993, (c) Kalle M. et al., 2013, (d) Nordahl 
E. A.  et al., 2004, (e) Sonesson A.  et al., 2011, (f) Sonesson A.  et al., 2011; Frick I. M.  et al., 2006, (g) 
Papareddy P. et al., 2010.
* putative CAMP.
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Table 9-B: cryptic CAMPs identified by analysis of peptides in body fluids.
Protein
(UniProt ID) Organism
Known 
cryptic 
CAMP/s 
(ref.)
Absolute 
maximum
S. aureus 
ATCC 
25923 
(score)
Local 
maxima 
S. aureus 
ATCC 
25923 
(score)
Score of 
known 
CAMPs 
S. aureus 
ATCC 
25923
Absolute 
maximum
P. aer.  
H103 
(score)
Relative 
maxima 
P. aer.  
H103 
(score)
Score of 
known 
CAMPs 
P. aer.  
H103
Fibrinogen beta 
chain (P02675)
Homo 
sapiens
45-72
(a)
195-212* 
(5.9)
40-77 
(5.2); 191-
212* (5.8)
2.4 195-212* (4.8)
40-77 
(3,3); 191-
212* (4.5)
1.4
Tissue factor 
pathway inhibitor 2 
(P48307)
Homo 
sapiens
202-235
(b)
204-235 
(13.7)
204-233 
(12.8); 
208-233 
(11.8)
11.5 204-235 (10.1)
204-233 
(9.2); 208-
233 (8.7)
8.2
References: (a) Påhlman L. I. et al., 2013, (b) Papareddy P. et al., 2012.
* putative CAMP.
Table 9-C: cryptic CAMPs identified for their physicochemical properties.
Protein
(UniProt ID) Organism
Known 
cryptic 
CAMP/s 
(ref.)
Absolute 
maximum
S. aureus 
ATCC 
25923 
(score)
Local 
maxima 
S. aureus 
ATCC 
25923 
(score)
Score of 
known 
CAMPs 
S. aureus 
ATCC 
25923
Absolute 
maximum
P. aer.  
H103 
(score)
Relative 
maxima 
P. aer.  
H103 
(score)
Score of 
known 
CAMPs P. 
aer. H103
Platelet factor 4 
(P02776)
Homo 
sapiens
89-101 
(a)
72-99 
(9.4)
76-99 
(8.7); 80-
99 (7.6)
4.2 72-99 (7.7)
76-99 
(7.1); 80-
99 (6.5)
3.4
Mucin-7
(Q8TAX7)
Homo 
sapiens
52-71
(b)
45-84 
(10.3)
51-74 
(9.3); 355-
371* (7.4)
7.0 45-84, 45-74 (7.6)
51-74 
(7.3); 355-
371* (6.5)
5.2
References: (a) Darveau R. P. et al., 1992, (b) Bobek L. A. and Situ H., 2003.
* putative CAMP.
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Table 9-D: cryptic CAMPs found in ribonucleases, lysozymes and lactotransferrins.
Protein
(UniProt ID) Organism
Known 
cryptic 
CAMP/s 
(ref.)
Absolute 
maximum
S. aureus 
ATCC 
25923 
(score)
Local 
maxima 
S. 
aureus 
ATCC 
25923 
(score)
Score of 
known 
CAMPs 
S. aureus 
ATCC 
25923
Absolute 
maximum
P. aer.  
H103 
(score)
Relative 
maxima P. 
aer. H103 
(score)
Score of 
known 
CAMPs P. 
aer. H103
Ribonuclease 
pancreatic 
(P07998)
Homo 
sapiens
29-76
(a)
57-75 
(4.5)
32-71 
(4.3)
29-68 
(3.2) 57-75 (3.1) 32-71 (2.5) 29-68 (1.7)
Non-secretory 
ribonuclease 
(P10153)
Homo 
sapiens
28-72
inactive
(a)
57-96 
(5.5)
28-67 
(3.1)
Eosinophil 
cationic protein 
(P12724)
Homo 
sapiens
28-71
(a)
34-72 
(9.1)
37-72 
(8.3); 34-
65 (7.9)
28-67
(8.5) 34-72 (6.8)
37-72 (6.3); 
34-65 (6)
28-67
(6.2)
Ribonuclease 4 
(P34096)
Homo 
sapiens
29-75
(a)
51-74 
(7.9)
55-74 
(7.1); 51-
84 (7.3)
29-68 
(3.2) 51-74 (6.2)
55-74 (5.7); 
51-84 (5.6) 29-68 (2.1)
Angiogenin 
(P03950)
Homo 
sapiens
25-71
inactive
(a)
53-80* 
(6.5)
48-81 
(6.3)
25-64 
(2.5) 53-80* (4.7) 48-81 (4.3) 25-64 (1.5)
Ribonuclease K6 
(Q93091)
Homo 
sapiens
24-68
(a)
88-127 
(5.7)
80-116 
(5.5)
24-63 
(4.7)
88-127 
(3.7)
80-116 
(3.6) 24-63 (3.1)
Ribonuclease 7 
(Q9H1E1)
Homo 
sapiens
29-73
(a)
103-140* 
(6.6)
29-66 (6);
106-140 
(6.3)
29-68 
(5.8)
103-140 
(4.2)
29-66 (3.8);
106-140 
(3.9)
29-68 (3.7)
Ribonuclease 8 
(Q8TDE3)
Homo 
sapiens
28-72
inactive
(a)
87-125 
(3.5)
82-121 
(3.2)
28-67 
(2.8)
87-125 
(2.1)
82-121 
(1.9) 28-67 (1.7)
Leukocyte 
ribonuclease A-2 
(Q27J90)
Gallus 
gallus
92-100; 
112-128
(b)
90-127 
(9.3)
94-130 
(8.5); 90-
124 (8.7); 
102-134 
(7.3)
- ; 3.3 90-127 (6.5)
94-130 
(5.9); 90-
124 (6.2); 
102-134 
(5.1)
- ; 2.1
Lysozyme C 
(P61626)
Homo 
sapiens
105-133; 
105-119; 
125-133
(c)
111-143, 
110-143 
(6.4)
/
1.1; 3.5; 
(125-136) 
3.0
26-52 (4.8)
111-143, 
110-143 
(4.4)
0.7; 2.4; 
(125-136) 
2.2
Lysozyme C 
(P00698)
Gallus 
gallus
105-132; 
105-118; 
125-132 
(c)
110-147, 
112-147, 
114-147 
(5.6)
/
1.0; 2.3; 
(125-136) 
3.0
110-147, 
114-147 
(3.9)
/
0.6; 1.4; 
(125-136) 
2.1
Lactotransferrin 
(P02788)
Homo 
sapiens
20-29; 39-
49 (d)
21-58 
(8.2)
37-58 
(6.5); 35-
58 (6.3)
(20-31) 
2.5; (39-
50) 3.7
21-58 (5.6) / (20-31) 1.6; (39-50) 2.7
Lactotransferrin 
(P24627) Bos taurus
36-60; 
287-303 
(e)
21-60, 22-
61, 22-60 
(12.1)
35-68 
(11.6); 
35-62 
(11.2);
285-320 
(7.9); 
285-308 
(6.8)
9.7; 4.1 22-60, 35-68 (9.3)
35-62 (9.1); 
285-320 
(5.9)
7.7; 2.8
References: (a) Torrent M. et al., 2013, (b) Nitto T. et al., 2006, (c) Ibrahim H. R. et al., 2001b, (d) Nibbering 
P. H. et al., 2001, (e) Hoek K. S. et al., (1997), van der Kraan M. I. A. et al., (2004) * putative CAMP.
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Table 9-E: cryptic CAMPs located in conserved regions.
Protein
(UniProt ID) Organism
Known 
cryptic 
CAMP/s 
(ref.)
Absolute 
maximum
S. aureus 
ATCC 
25923 
(score)
Local 
maxima 
S. aureus 
ATCC 
25923 
(score)
Score of 
known 
CAMPs 
S. aureus 
ATCC 
25923
Absolute 
maximum
P. aer.  
H103 
(score)
Relative 
maxima 
P. aer.  
H103 
(score)
Score of 
known 
CAMPs P. 
aer. H103
Coagulation factor X 
(P00742)
Homo 
sapiens
448-467 
(a)
443-475, 
444-475, 
445-475 
(9.1)
448-475 
(7.9); 436-
475 (8.9)
5.3
443-475, 
444-475, 
445-475 
(6.6)
436-475 
(6.4); 445-
473 (6.2)
4.1
Granzyme H 
(P20718)
Homo 
sapiens
225-244 
(a)
215-246 
(9.3)
221-246 
(8.7); 228-
246 (8.1)
5.9 215-246 (7.2)
221-246 
(6.8); 228-
246 (6.9)
4.7
Laminin subunit 
beta-1 (P07942)
Homo 
sapiens
223-239 
(b)
223-243 
(8.1)
220-243 
(7.8); 227-
243 (7.1)
7.4
223-243, 
223-240 
(6.9)
220-243 
(6.4) 6.2
Plasma serine 
protease inhibitor 
(P05154)
Homo 
sapiens
283-302 
(b)
285-308 
(10.5)
285-299 
(8.4); 369-
405* (9)
6.3 285-308 (8.8)
287-306 
(8.4); 369-
405* (7.3)
4.9
Coagulation factor X and granzyme H are serine proteases containing an antimicrobial region at the C-
terminus,  with  the  conserved  pattern  X-[PFY]-X-[AFILV]-[AFY]-[AITV]-X-[ILV]-X(5)-W-[IL]-X,  while  laminin 
subunit beta-1 and plasma protease inhibitor are proteins containing an heparin-binding domain.
References: (a) Kasetty G. et al., 2011b, (b) Andersson E. et al., 2004.
* putative CAMP.
Our strategy, in almost all cases, identifies the antimicrobial regions described in literature. 
When the highest scoring peptide does not match exactly the known peptide, the known 
CAMP is always contained inside the highest scoring peptide. We want to underline that  
the new absolute maxima identified in kininogen-1, complement C3 and heparin cofactor 2 
(Table 9-A) are located in regions not studied by the authors of the works cited, and thus 
they are new putative antimicrobial agents.
In the case of fibrinogen beta chain (Table 9-B), the peptide receives a very low score and 
the  function  identifies  a  “weak”  absolute  maximum in  another  region  not  studied;  this 
peculiar peptide is more active towards Group A and Group B streptococci, in particular if  
entrapped in the fibrin cloth, and thus, apparently, its mechanism of action could deviate 
from the  behaviour  of  conventional  CAMPs.  The  antimicrobial  peptide  of  tissue  factor 
pathway  inhibitor  2  (Table  9-B),  cleaved  by  neutrophil  elastase,  is  instead  perfectly 
recognized.
The highly cationic and hydrophobic N-terminus of eosinophil cationic protein (Table 9-D) 
is highlighted by the prediction system, while new putative CAMPs are located towards the 
C-terminus of angiogenin and ribonuclease 7. Finally, the antimicrobial regions of chicken 
RNase A-2, lysozymes and lactotransferrins are well recognized. The analysis  of human 
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ribonucleases leads to two false negatives: pancreatic ribonuclease and ribonuclease K6. 
As for the case of fibrinogen beta chain, these fragments are weakly hydrophobic and with 
a low content of positive charges, thus they could act by a mechanism different from that  
of classic CAMPs.
The great majority of the hidden CAMPs located in heparin-binding domains and at the C-
terminus of serine proteases are very weak CAMPs. These peptides are particular rich in 
cationic and hydrophilic residues and lack hydrophobic residues; their action is very often 
abolished when antibacterial  assays are conducted in presence of salt  and sometimes 
have little activity even at physiological conditions (Pasupuleti M. et al., 2009; Malmsten M. 
et al.,  2006; Kasetty G.  et al.,  2011b).  Therefore we have analyzed only few of these 
peptides endowed with good antimicrobial activity (Table 9-E).
Table 9-F reports the analysis of antimicrobial peptides secreted as proproteins.
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Table 9-F: “conventional” antimicrobial peptides secreted as proproteins.
Protein
(UniProt ID) Organism
Known 
cryptic 
CAMP/s*
Absolute 
maximum
S. aureus 
ATCC 
25923 
(score)
Local 
maxima S. 
aureus 
ATCC 
25923 
(score)
Score of 
known 
CAMPs S. 
aureus 
ATCC 25923
Absolute 
maximum
P. aer. H103 
(score)
Relative 
maxima P. 
aer. H103 
(score)
Score of 
known 
CAMPs P. 
aer. H103
Protegrin-1 
(P32194) Sus scrofa 131-148
130-148 
(6.3) / 5.9
130-148 
(4.7) / 4.3
Protegrin-2 
(P32195) Sus scrofa 131-146
130-146 
(6.1) / 5.8
130-146 
(4.8) / 4.4
Protegrin-3 
(P32196) Sus scrofa 131-148
130-148 
(5.2) / 4.9
130-148 
(3.9) / 3.5
Protegrin-4 
(P49933) Sus scrofa 131-148
130-148 
(5.3) / 5.0
130-148 
(4.1) / 3.8
Protegrin-5 
(P49934) Sus scrofa 131-148
130-148 
(5.5) / 5.1
130-148 
(4.1) / 3.8
Cathelicidin 
antimicrobial 
peptide (P49913)
Homo 
sapiens
132-170; 
134-170
130-167 
(11.8)
130-162 
(10.3); 
138-167 
(9.8)
8.0; 7.6 130-167 (9.2)
130-162 
(8.0); 138-
167 (7.6)
6.0; 5.6
Cathelicidin-1 
(Q6QLQ5) Gallus gallus 123-148
122-148 
(11.2)
125-147 
(8.7) 10.9
122-148 
(9.2)
125-147 
(7.2) 9.2
Cathelicidin-4 
(P33046) Bos taurus 131-143
130-143 
(6.4) / 6.3
130-143 
(5.9) / 5.8
Prophenin and 
tritrpticin precursor 
(P51524)
Sus scrofa 112-124; 131-209
113-152 
(12.9)
112-129 
(11.6); 117-
129 (8.6); 
121-152 
(8.6)
7.6; - 112-129 (10.5)
112-132 
(10.3); 117-
152 (8.2)
7.1; -
Cathelicidin-2 
(Q2IAL7) Gallus gallus 123-154
122-153 
(12.7)
126-147 
(11); 128-
143 (9.7)
12.0 122-153, 122-147 ()
126-147 
(9.0); 128-
143 (8.2)
9.4
Cathelicidin-3 
(Q2IAL6) Gallus gallus 123-151
122-151 
(10.1) / 9.9
122-151 
(8.2) / 7.9
Cathelicidin-1 
(P22226) Bos taurus 144-155
130-153 
(7.2) /
(143-155) 
4.8
130-153 
(5.7) /
(143-155) 
4.0
Cathelicidin-2 
(P19660) Bos taurus 131-173
130-169 
(13.7)
141-169 
(8.3); 149-
176 (8.5)
(131-170) 
13.2
130-169 
(11.2)
136-162 
(7.4); 149-
176 (6.8)
(131-170) 
10.6
Cathelicidin-3 
(P19661) Bos taurus 131-189
127-166 
(13.8)
146-180 
(10.3); 
156-184 
(8.3)
(131-170) 
13.6
127-166 
(10.6); 130-
166 (10.6)
139-174 
(8.6); 156-
188 (7.3)
(131-170) 
10.2
Cathelicidin-5 
(P54229) Bos taurus 132-159
134-158 
(11.4)
137-158 
(10.0); 
139-158 
(9.8)
10.3 134-158 (9.8)
137-158 
(8.7); 139-
158 (8.5)
8.4
Cathelicidin-6 
(P54228) Bos taurus 132-158
133-157 
(15.2)
133-152 
(12.6); 
128-157 
(14.9)
14.2 133-157 (13.3)
133-155, 
128-157 
(12.6)
12.0
Cathelicidin-7 
(P56425) Bos taurus 131-164
133-164 
(9.3)
128-164 
(9.1) 9.0
133-164 
(7.0)
128-164 
(6.6) 6.6
Histon H2A 
(O13260)
Bufo 
gargarigans 16-36 5-43 (9.4) 9-36 (8.9) 5.4 5-43 (6.4) 9-36 (6.3) 4.0
Alpha-defensin 1 
(P11477)
Mus 
musculus 59-93 59-93 (7.1) / 7.1 59-93 (4.9) / 4.9
* the location of the antimicrobial peptides was taken from the UniProt sequence annotations.
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The  antimicrobial  peptides  in  table  9-F  are  in  all  the  cases  located  in  the  absolute  
maximum of the scoring function, and often the minimal discrepancies at the extremities 
are due to the inclusion in the highest scoring peptide of the cleavage signals that, often, 
are pair of basic residues.
In conclusion, our scoring function properly identifies almost all the hidden antimicrobial 
domains here reported, failing only in the case of non-canonical CAMPs with a low content 
of positive residues and/or hydrophobic residues, that likely are not well described by the  
model in figure 7.
A more  complete  validations  will  be  performed  by  automating  the  calculation  of  the 
absolute score, in order to analyse larger pools of known CAMP precursors. For example, 
at the moment, more than 190 cathelicidins and 140 α-defensins have been described.
Finally, an experimental validation has been performed by preparing and characterizing a 
new CAMP contained inside human apolipoprotein E, as described in the next section.
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EXPERIMENTAL SECTION
3.3 A novel fusion system for the recombinant expression of CAMPs
The production of large quantities of pure peptides is crucial for biological, biophysical and 
structural studies. The direct isolation from the organism is difficult and time-consuming, 
whereas chemical synthesis has high costs, especially when high purity, high quantities,  
long peptides or 15N/13C labeled peptides are needed. An economical alternative is given 
by the recombinant expression of peptides in  Escherichia coli, one of the most diffused 
host. However, as direct expression of CAMPs in a bacterial host is made complex by their 
toxicity, usually CAMPs are produced as fusion proteins. The carrier in the fusion system 
protects the peptide from proteolytic cleavage and at the same time masks it, abolishing or 
reducing  its  toxicity.  Two  kinds  of  carriers  are  usually  employed:  solubility-enhancing 
carriers,  like  thioredoxin,  glutathione  transferase  and  small  ubiquitin-related  modifier 
(SUMO), and aggregation-promoting carriers, like ketosteroid isomerase. The formation of 
aggregates, called inclusion bodies, permits to protect more efficiently the peptide from 
degradation and the bacterial cell from the toxicity of the antimicrobial agent. Moreover,  
inclusion bodies allow a more rapid purification of the fusion proteins. The peptide can be 
isolated from the fusion construct using chemical reagents like cyanogen bromide, formic 
acid  and hydroxylamine,  which,  however,  can modify some side chains of  the peptide 
(residues  like  cysteine,  methionine,  tryptophan  but  also  lysine,  serine,  threonine  and 
histidine often  undergo undesired reactions).  Alternatively,  the peptide  can be cleaved 
using proteases like enterokinase, thrombin, factor Xa etc.. Specific proteases are more 
selective than chemical reagents and do not damage sensitive residues of the peptide, but 
they are expensive, the yields are unpredictable and sometimes very low – e.g. when the 
cleavage site is partially hidden and/or unfavorable surrounding residues are present. TEV 
and SUMO proteases are still active in mild denaturing conditions that, inducing a less 
compact structure of the fusion protein, allow higher cleavage yields. Generally, proteases 
cannot be used when the fusion proteins are insoluble and/or extracted from inclusion 
bodies using strong denaturing conditions. Finally, there are also two examples of self-
cleavable carriers: inteins, which excise themselves as introns, but can be prone to an 
uncontrolled auto-cleavage, and the N-terminal protease Npro of classical swine fever virus, 
which instead needs extensive dilution,  long incubation times and the cleavage is  not 
complete (Li Y., 2011).
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In collaboration with the group of Dr. Valeria Cafaro (Department of Biology, Federico II 
University, Naples) I have developed a new fusion system which allows to obtain very high 
yields  of  recombinant  peptides without  using  expensive  proteases  or  harsh  cleavage 
conditions.  We chose  to  express  CAMPs as  fusion  proteins  by  attaching  the  desired 
peptide to the C-terminus of (M23L)-onconase (ONC), a frog ribonuclease (Figure 13). 
ONC is a very well suited partner for several reasons (Notomista E. et al., 1999): (i) it can 
be expressed at very high levels as inclusion bodies (about 150 mg/L in Terrific Broth); (ii) 
no soluble onconase can be detected in the cultures, thus minimizing the risk of  toxic 
effects of the CAMPs; (iii) it is a very small protein (104 aa), thus allowing higher yields of  
the peptides after the cleavage. Moreover, denatured ONC extracted from inclusion bodies 
is soluble at acidic pH (<4), but completely insoluble at pH 7. Therefore, if the cleavage of 
the  fusion  protein  is  performed  at  acidic  pH  –  or  at  neutral  pH  in  the  presence  of  
denaturants (e.g. guanidinium chloride) – and successively the pH is increased to 7 – or 
the denaturants are removed – ONC forms precipitate, whereas the majority of the CAMPs 
will remain in solution, thus allowing a very simple purification of the peptide. Moreover, 
ONC does not contain methionine residues, Asp-Pro or Asn-Gly dipeptides, thus allowing 
to cleave the desired peptide using the three most common chemical cleavage reagents: 
cyanogen bromide (CNBr), which cleaves at the C-side of methionine, formic acid, which 
cleaves the bond between aspartate and proline, and hydroxylamine, which cleaves the 
bond between asparagine and glycine (Li Y., 2011).
Figure 13: schematic representation of the novel fusion construct ONC-ThrAP.
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In order to optimize this method we have prepared a fusion protein between ONC and the 
human  Thrombin-derived  Antimicrobial  Peptide,  ThrAP,  a CAMP well  described in  the 
literature (Kasetty G.  et al., 2011a), that we have chosen as positive control. The acid-
cleavable sequence GTGDP was inserted between ONC and ThrAP.
The initial fusion protein ONC-ThrAP has been expressed effectively in E. coli with a yield 
of  about 150 mg per liter of culture in Terrific  Broth. Moreover,  the fusion protein was  
present exclusively in the insoluble fraction of cell  lysates, thus confirming that ONC is 
able to efficiently deliver ThrAP to inclusion bodies. After denaturation of purified inclusion 
bodies and dialysis in an acidic buffer (pH 3), the fusion protein was heated at 60°C to 
perform the selective hydrolysis of the Asp-Pro bond.
Different acids were tested:
I. 70% formic acid (the reaction mixture usually described in literature (Landon M., 
1977));
II. 0.1 M acetic acid, pH 3;
III. 10 mM HCl, pH 2;
IV. 0.1 M acetic acid/HCl, pH 2.
These analysis revealed that the mixture of acetic and hydrochloric acid at pH 2 allows to  
obtain an high efficient cleavage (>90%), avoiding the use of formic acid which at high 
concentrations can give undesired reactions (e.g. formylation of serine and threonine Li Y.,  
(2011)). Interestingly, acetic acid (pH 3.0) or HCl (pH 2.0) alone gave very low cleavage 
yields suggesting that both pH 2.0 and the presence of acetic acid are necessary to obtain 
the cleavage. An intriguing hypothesis is that acetic acid, which at pH 2.0 is completely 
undissociated, acts as a catalyst. However, this aspect has not been further investigated.
Unfortunately, these first attempts also revealed two unexpected problems:
I. The mild acidic hydrolysis (independently from the acid used) cleaves ONC in three 
fragments, in spite of the fact that it does not contain Asp-Pro dipeptides.
II. Some  E. coli proteins, present in small amount as contaminants in the inclusion 
bodies,  during  the  mild  acidic  hydrolysis  release  small  fragments  of  length 
comparable to that of ThrAP.
When the pH of samples was increased from 2 to 7, uncleaved ONC and E. coli proteins 
precipitated  completely,  whereas  the  shortest  fragments  released  from these  proteins 
remained in solution as contaminants, thus making more complex the purification of ThrAP.
By N-terminal  sequencing and mass spectrometry analysis  of  the fragments,  we have 
assessed that two Asp-Cys dipeptides contained in the ONC sequence (at positions 18 
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and 67) undergo acid-catalyzed hydrolysis at almost the same efficiency of the Asp-Pro 
dipeptide,  a  result  not  described in  literature  that  suggests  the  intriguing  possibility  to 
prepare recombinant peptides with a single additional cysteine at the N-terminus.
Moreover, at least two other Asp-X sequences of ONC were hydrolyzed with a very low 
efficiency (1-2%).
In  order  to  solve  these  problems  and  to  optimize  the  purification  of  ThrAP,  I  have 
characterized a series of mutated fusion proteins described in the table 10.
Table 10: mutated fusion proteins for the optimization of the carrier.
Protein Mutated ONC residues / insertion of His6
ONC-YY-ThrAP C19Y,C68Y
ONC-EYEY-ThrAP D18E,C19Y,D67E,C68Y
ONC-EYEY-His-ThrAP D18E,C19Y,D67E,C68Y / His6
ONC-DCless-His-ThrAP
D2E,D16E,D18E,D20E,D32E,D67E,C19Y,C30Y,C48L,C68Y,C75Y,C87I, 
C90I / His6
The  His6 tag  has  been  added  to  purify  the  fusion  proteins  by  Nickel-chelate  affinity 
chromatography. This chromatographic technique can be performed also in the presence 
of  denaturants.  Therefore,  it  allows  to  purify  the  fusion  proteins  immediately  after 
denaturation of inclusion bodies, thus reducing time and the number of steps necessary to 
obtain a purified fusion protein suitable for the mild acidic hydrolysis. The mutations in the 
ONC  sequence  were  chosen  to  determine  the  minimal  changes  necessary  to  avoid 
fragmentation of the carrier without changing the expression level of the fusion protein and 
the pH dependent solubility of ONC. We decided to prepare also a mutant with no cysteine 
residue (ONC-DCless-His-ThrAP), to reduce the possibility of unwanted oxidations and the 
formation of intra- and inter-chain disulphides. Moreover, this ONC mutant could be used 
to  cleave peptides by reagents specific  for  cysteines (e.g.  2-nitro-5-thiocyanatobenzoic 
acid (Ryan R. O. et al., 2003)) as an alternative to acid-catalysed hydrolysis.
Since the solubility and tendency to form aggregates - like inclusion bodies - of a protein is  
generally related to its net charge and hydrophobicity, but also to its secondary structure, 
the  amino  acidic  substitutions  were  chosen  in  order  to  preserve  these  properties. 
Therefore, aspartic acid residues were replaced with glutamic acid residues in order to 
preserve the net charge. In the case of cysteine residues, we considered hydrophobicity 
and  propensity  to  form  specific  secondary  structures.  Cysteine  residues  adjacent  to 
aspartic acid (DC sequences) were replaced with tyrosine residues. The replacement of a 
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dipeptide DC with EY allows to keep unchanged the secondary structure propensity, in 
fact, the replacement aspartate / glutamate decreases the preference for loop structures, 
whereas the cysteine / tyrosine substitution increases the preference for loop structures. 
The cysteine residues not adjacent to residues of aspartic acid were replaced on the basis 
of secondary structure of native ONC (PDB code: 1ONC). Accordingly, the single cysteine 
residue present within α-helix 3 was replaced with a leucine residue (an “helix-preferring” 
residue). Two cysteine residues located in β-strands were replaced with isoleucine (a “β-
preferring”  residue).  Finally,  two cysteine residues located in loops were replaced with 
tyrosine residues.
All the mutated fusion proteins were expressed with a yield similar to, or even higher, that  
of ONC-ThrAP and entirely in the insoluble fraction, thus demonstrating that the chosen 
mutations do not interfere with the formation of inclusion bodies. Moreover, the mutations 
progressively reduced the number of unwanted cleavage sites. In particular, by changing 
the  DC sequences to  DY (ONC-YY-ThrAP) we obtained a drastic  reduction but  not  a 
complete abolition of unwanted hydrolysis. Only replacing the residue of aspartate with 
glutamate  (ONC-EYEY-ThrAP)  it  was  possible  to  completely  abolish  the  hydrolysis  at 
these two sites. The analysis of ONC-EYEY-ThrAP has however shown that this protein 
still  undergoes  hydrolysis  at  other  aspartic  residues,  as  suggested  by  the  mass 
spectrometry analysis on the first fusion protein. Finally, the hydrolysis of the protein ONC-
DCless-His-ThrAP led  to  two  protein  bands  of  molecular  weight  corresponding  to  the 
carrier and ThrAP. The SDS-PAGEs in figure 14 display the different patterns of hydrolysis 
of the variants of the fusion construct, while the SDS-PAGE in figure 15 recapitulates the 
purification steps of recombinant ThrAP, starting from the final optimized variant,  ONC-
DCless-His-ThrAP.
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Figure 14: comparison of the acidic hydrolysis patterns of ONC-ThrAP (A), ONC-YY-ThrAP (B), 
ONC-EYEY-His-ThrAP (C) and ONC-DCless-His-ThrAP (D). The samples were analyzed on 20% 
SDS-PAGE.  Lanes 1:  Gallus gallus lysozyme (14 kDa, 2  μg);  lanes 2: fusion construct  (5  μg); 
lanes 3: cleaved fusion construct (5 μg).
                                   1         2        3       4       5      6       7        8                9
Figure 15:  20% SDS-PAGE of  the  purification  steps  of  recombinant  ThrAP.  Lane 1:  induced 
culture (0.063 OD);  lane 2: soluble fraction after cell lysis (0.063 OD);  lane 3: insoluble fraction 
after cell lysis (0.063 OD);  lane 4:  insoluble fraction after the preliminary purification (0.063 OD); 
lane 5: purified fusion construct after IMAC (5 μg); lane 6: cleaved fusion construct (5 μg); lane 7: 
soluble fraction after alkalinization of the cleavage reaction (5 μg); lane 8: insoluble fraction after 
alkalinization of the cleavage reaction (5 μg); lane 9: Gallus gallus lysozyme (14 kDa, 2 μg).
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After the precipitation step at pH 7, the peptide, analyzed by mass spectrometry by Dr.  
Andrea Carpentieri (Department of Chemistry, University Federico II, Naples), showed a 
molecular weight of 2609.47 Da (Figure 16), almost identical to the expected one (2609.1 
Da), and a purity >98%.
Figure 16: mass spectrum of purified ThrAP.
On the basis of several preparations, I have estimated an average yield of about 7-10 mg 
of ThrAP per liter of broth. These results confirm that ONC-DC less is an optimal carrier for 
the preparation of recombinant CAMPs and that our method is competitive with respect to  
conventional chemical synthesis of peptides.
Moreover,  Dr.  E.  Pedone and co-workers (Istituto  di  Biostrutture e Bioimmagini,  CNR, 
Naples; personal communication), using ONC-EYEY-His, have successively prepared the 
21 aa peptide PHGLASTLTRWAHYNALIRAF (a membrane translocation peptide derived 
from herpes simplex virus type 1 glycoprotein H (Falanga A. et al., 2011)) with yields of 7 
mg per liter of culture in the case of the non-labeled peptide, and 1.9 mg per liter of culture 
in  the  case  of  the  15N-labeled  peptide,  thus  demonstrating  that  the  carriers  we  have 
developed allow the efficient preparation of labeled peptides for NMR studies.
3.4 Development and optimization of a new rich broth
Recombinant  proteins  are  generally prepared using  very rich  and complex  broths  like 
Luria-Bertani or Terrific Broth. Usually these broths give high expression levels. However, 
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unfortunately, the reproducibility is low. The variability has been attributed prevalently to 
yeast  extract  which  shows  differences  in  the  composition  not  only  depending  on  the 
manufacturer, but also from batch to batch of the same manufacturer (Huang C.-Jr et al., 
2012)
For this reason, I have contributed to the development and optimization of a new Semi-
Defined  Rich  Medium (SDRM) in which the yeast extract was completely replaced with 
nutrient with defined – or less undefined – composition (Table 11).
Table 11: comparison between TB and SDRM composition.
ORGANIC COMPONENTS TB SDRM
Yeast extract 24 g/L -
Trypton 12 g/L 34 g/L
Glycerol 4 ml/L 12 ml/L
Glucose - 4 g/L
Betaine - 1 mM
BUFFER COMPONENTS
KH2PO4 2.31 g/L 2.31 g/L
K2HPO4 12.54 /L 12.54 /L
(NH4)3Citrate - 15 mM
Micronutrients - +
Yeast  extract  was  prevalently  substituted  with  trypton,  which,  being  an  hydrolyzate  of 
bovine casein, has a defined amino acidic composition. As different batches of trypton can 
contain  different  amounts  of  lactose which could determine undesired induction of  the 
recombinant proteins, we have added glucose to the medium. Glucose acts as a repressor 
of lac promoter and prevents the induction of the T7-RNA-polymerase of the BL21(DE3) E. 
coli strain until the addition of IPTG. Our SDRM contains also a mixture of salts providing 
all  the necessary metals  at  optimal  concentration (e.g.  Mg,  Ca, Zn,  Fe,  Mn, Cu etc.).  
Ammonium citrate was added both as a source of inorganic nitrogen and as an additional  
buffer. Moreover, citrate, acting as a chelating agent, avoids the precipitation of transition 
metal cations. Finally, betaine was added to the medium as this compound is one of the  
best  osmolytes  for  E.  coli.  This  bacterium can  synthesize  betaine  from  choline,  a 
component likely present in yeast extract but not in trypton.
Using our SDRM we have reproducibly obtained about 180 mg of protein/L of medium, a 
result only occasionally obtained with “the best preparations” of Terrific Broth.
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3.5 Selection and preparation of a panel of promising new hypothetical 
CAMP
On the basis of the results described in the bioinformatic section we selected six small to 
medium sized promising hypothetical human CAMPs (from 18 to 47 aa) (Table 12):
I. a 18 aa peptide derived from apolipoprotein E (ApoE-AP, Apolipoprotein E-derived 
Antimicrobial Peptide);
II. three peptides derived from the C-termini  of  fibrinogen alpha,  beta and gamma 
subunits (α-, β-, γ-FAP, α-, β-,γ-Fibrinogen-derived Antimicrobial Peptide); 
III. a  47  aa peptide  derived from pepsin  activation  peptide  (PA3-AP,  the  activation 
peptide of pepsinogen A3);
IV. a 29 aa peptide derived from isoform 2 of hydroxysteroid 11-beta-dehydrogenase 1-
like protein (H11bD1-AP).
Table 12: primary structure of the six selected novel hypothetical cryptic CAMPs.
Peptide UniProt ID position Primary structurea
ApoE-AP P02649 151-168 LRVRLASHLRKLRKRLLR
α-FAP P02671 841-866 GVVWVSFRGADYSLRAVRMKIRPLVTQ
β-FAP P02675 464-491 GVVWMNWKGSWYSMRKMSMKIRPFFPQQ
γ-FAP P02679 392-421 GIIWATWKTRWYSMKKTTMKIIPFNRLTIG
PA3-AP P0DJD8 16-62 IMYKVPLIRKKSLRRTLSERGLLKDFLKKHNLNPARKYFPQWKAPTL
H11bD1-AP Q7Z5J1-2 250-276 GVFYPWRFRLLCLLRRWLPRPRAWFIR
a basic residues are colored in blue, hydrophobic residues in green, borderline residues in gray, hydrophilic  
residues in yellow, acidic residues in red.
All these peptides were expressed as fusion proteins with ONC-DCless by the groups of 
Dr. V. Cafaro and Dr. E. Pizzo (Department of Biology, Federico II University, Naples), with 
yields  similar  or  higher  than that  of  ThrAP,  thus demonstrating  that  our  strategy is  of 
general utility and can be used also to express peptides longer than ThrAP (at least up to  
47 aa).
For the sake of brevity, I will describe only the considerations that led us to choose ApoE-
AP. The presence of an antimicrobial peptide in apolipoprotein E was described by Dobson 
C.  B.  et  al.,  (2006).  They selected a 9 aa peptide of  ApoE coming from the receptor 
binding  region  of  the  protein.  This  sequence,  however,  is  a  very  weak  antimicrobial 
peptide, and so Dobson C. B. and coworkers prepared an artificial head to tail “duplicated” 
peptide with a good antimicrobial  activity.  The analysis of the ApoE sequence with our 
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strategy,  on  the  other  hand,  suggests  that  a  18  aa  peptide,  including  the  previously 
identified 9 aa peptide, could be a very effective CAMP (with a relative score close to 0.5,  
this peptide is one of the highest scoring peptides with length <20 aa). The comparison 
between  the  artificial  “duplicated”  peptide  and  the  peptide  we  have  identified  reveals 
intriguing similarities (Table 13). The colours in table 13 also highlight some interesting 
differences in the composition and distribution of residues in ThrAP and ApoE-AP: ApoE-
AP is rich in aliphatic residues and contains homogeneously distributed basic and aliphatic 
residues, whereas ThrAP is rich in aromatic residues and shows a C-terminal amphipathic 
domain (helical in thrombin, see figure 19, paragraph 3.7) and a N-terminal aromatic and 
hydrophobic domain (extended in thrombin, see figure 19, paragraph 3.7).
Table 13: primary structure of the “duplicated” ApoE derived peptide, ApoE-AP and ThrAP.
Peptide Primary structurea Net charge
“duplicated” peptide
     LRKLRKRLLLRKLRKRLL 
     ├repeat1┤├repeat2┤ +10
ApoE-APb       LRVRLASHLRKLRKRLLR +8
ThrAPb     GKYGFYTHVFRLKKWIQKVI +5
a basic  residues  are  colored  in  blue,  aliphatic  and  aromatic  residues  in  green  and  cyan  respectively,  
borderline residues in gray, hydrophilic residues in yellow.
b recombinant peptides produced as fusion proteins with ONC-DCless have an additional proline at the N-
terminus derived from the acid-labile sequence Gly-Asp-Pro.
3.6 Antibacterial activity of recombinant ThrAP and ApoE-AP
The novel antimicrobial peptide ApoE-AP was produced by Dr. E. Pizzo’s group using the 
strategy described above and characterized along with the control peptide ThrAP.
The antibacterial  activity of the recombinant peptides was assessed on a lab strain of  
Staphylococcus aureus (ATCC 6538P, Gram-positive bacterium) and on a clinical isolate of 
Pseudomonas  aeruginosa (KK27,  Gram-negative  bacterium),  kindly  provided  by  D. 
Alessandra Bragonzi (San Raffaele Hospital, Milan).  The results in figure 17 show that 
ApoE-AP is more active than the control peptide ThrAP on both strains.
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Figure 17: antibacterial activity of the recombinant peptides towards Staphylococcus aureus ATCC 
(A) and Pseudomonas aeruginosa KK27 (B). The relative error was always lower than the 10% of 
the measure.
3.7 Structural characterization of recombinant ThrAP and ApoE-AP
Circular dichroism studies were performed to characterize ThrAP and ApoE-AP in different 
environments. The two peptides were largely unordered in buffer, while TFE and SDS, two 
membrane-mimicking agents (see paragraph 1.3), induced a pronounced α-helix in both 
(Figure 18).
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Figure 18: CD spectra of the recombinant peptides in buffer and in the presence of membrane-
mimicking agents.  In  blue:  spectra registered in  sodium-phosphate  10 mM pH 7.4;  in  green: 
spectra registered in SDS 20 mM; in brown: spectra registered in TFE 30%.
Secondary structure content was estimated through the PEPFIT tool (Reed J. and Reed T. 
A., 1997), and the results are shown in table 14.
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Table 14: secondary structure content  estimated from circular  dichroism spectra in  phosphate 
buffer and in the presence of membrane-mimicking agents.
Random coil α β turn R2
ThrAP buffer 47% / / 53% 0.9979
ApoE-AP buffer 72% 10% 13% 5% 0.9927
ThrAP + SDS 20 mM 28% 32% 8% 32% 0.9793
ApoE-AP + SDS 20 mM 14% 50% / 36% 0.9923
ThrAP + TFE 10% 42% / / 58% 0.9941
ApoE-AP + TFE 10% 69% 8% 15% 8% 0.9965
ThrAP + TFE 30% 2% 51% / 47% 0.9868
ApoE-AP + TFE 30% 18% 69% / 13% 0.9945
ThrAP + TFE 50% / 57% / 43% 0.9826
ApoE-AP + TFE 50% 14% 74% / 12% 0.9938
ThrAP + TFE 70% / 54% / 46% 0.9859
ApoE-AP + TFE 70% 13% 78% / 9% 0.9946
The value of R2 is a measure of the discrepancy between the experimental spectrum and the calculated one 
obtained with the PEPFIT tool; a value of 1 indicates a perfect match between the spectra.
It  is  worth  noting  that  the  helix  content  did  not  exhibit  a  significant  change  at 
concentrations of TFE higher than 30%, denoting a high propensity to acquire an ordered 
structure; peptides with pronounced helical-propensity reach, in fact, the maximum helical  
content at concentrations of TFE between 30% and 50% (Sönnichsen F. D. et al., 1992).
However, it should be noted that in all the conditions tested ApoE-AP has a helix content 
significantly  higher  than  ThrAP.  This  could  indicate  that  the  isolated  peptides,  in  the 
presence of structure-inducing compounds (TFE, SDS), tend to adopt structures similar to 
those  seen  in  the  intact  proteins  (Figure  19):  in  the  ApoE  structure  the  peptide 
corresponding to ApoE-AP is entirely helicoidal, whereas in the thrombin structure, only 10 
out of 20 residues of the region corresponding to ThrAP adopt an helical conformation (the 
last ten residues of ThrAP).
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Figure 19: comparison between the structure of ThrAP (in  green) and ApoE-AP (in  red) in the 
respective entire proteins (PDB codes: 1PPB for thrombin and 2L7B for ApoE). The molecules are 
depicted with the N-terminus up and the C-terminus down.
To further  characterize  the  structural  and biological  properties  of  the  two  peptides we 
studied  their  binding  to  alginate  and  LPS,  two  bacterial  molecules  of  great  biological  
relevance:  alginate,  an  acidic  polysaccharide,  can  sequester  antimicrobial  peptides 
inhibiting their action, whereas LPS, the main constituents of the outer membrane of Gram 
negative  bacteria,  are  “endotoxins”  that  can  induce  septic  shock.  Some  CAMPs,  in 
addition to antimicrobial activity, can bind and neutralize LPS thus preventing septic shock 
(see paragraph 1.1). The binding of ThrAP to LPS has already been described by Kasetty 
G. et  al.,  (2011a):  LPS  induced  an  helical  structure  and  the  peptide  displayed  an 
immunomodulatory activity  in vivo in macrophage cultures. Therefore we compared the 
binding of ThrAP and ApoE-AP to LPS and alginate.
At similar concentrations (about 3-fold higher than the work previously cited), ThrAP and 
ApoE-AP reacted differently to both alginate and LPS: ThrAP aggregated in the presence 
of LPS and, at a minor extent, also in presence of alginate; on the contrary,  ApoE-AP 
remained  soluble  in  both  conditions.  The  addition  of  sodium  chloride  reduced  the 
aggregation (data not shown), but it was abolished only at very low ThrAP concentrations. 
The spectra obtained with the ligands are in figure 20.
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Figure 20:  CD spectra of the recombinant peptides in buffer and in the presence of LPS and 
alginate.  In  blue:  spectra  registered  in  sodium-phosphate  10  mM  pH  7.4;  in  green:  spectra 
registered in the presence of alginate 0.2 mg/mL; in light blue: spectra registered in the presence 
of LPS 0.2 mg/mL. Only for ThrAP, at a concentration of 10 μM, two other spectra with LPS (olive 
green) and alginate (brown) were recorded.
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Secondary  structure  content  was  estimated  as  described  before,  and  the  results  are 
shown in table 15.
Table 15: secondary structure content estimated from circular dichroism spectra in the presence of 
LPS and alginate.
Random coil α β turn R2
ThrAP + LPS 0.2 mg/mL 9% 20% / 71% 0.9636
ThrAP (10 uM)* + LPS 0.2 mg/mL / 22% 20% 58% 0.9907
ApoE-AP + LPS 0.2 mg/mL 45% 14% 22% 19% 0.9949
ThrAP + alginate 0.2 mg/mL / 45% / 55% 0.9621
ThrAP (10 uM)* + alginate 0.2 mg/mL 3% 52% / 45% 0.9581
ApoE-AP + alginate 0.2 mg/mL 48% 13% 17% 22% 0.9930
The value of R2 is a measure of the discrepancy between the experimental spectrum and the calculated one 
obtained with the PEPFIT tool; a value of 1 indicates a perfect match between the spectra.
* diluted solutions which displayed no aggregation.
ApoE-AP's spectra are indicative of a relative small perturbation of the random-coil state,  
whereas ThrAP's spectra suggest a more relevant conformational change induced by the 
ligands. Bhunia A. et al., (2009) found that the antimicrobial peptide fowlicidin-1, which has 
two LPS-binding regions, aggregated in presence of LPS. Interestingly the two regions,  
once  separated,  remained  soluble  in  the  presence  of  LPS.  This  observation  lets  to 
propose the hypothesis that only peptides with multiple LPS-interaction sites cause the 
aggregation phenomenon. As discussed above, ThrAP shows the presence of two distinct 
regions,  an extended more hydrophobic  region at  the  N-terminus and an amphipathic 
helical  charged  region  at  the  C-terminus  which  could  behave  as  distinct  LPS-binding 
modules. Further studies will be necessary to confirm this hypothesis. Finally, it should be 
noted that ThrAP has several aromatic residues which, as underlined in  Pulido D.  et al., 
(2011), play a fundamental role in LPS interaction. On the contrary no aromatic residue is 
present in ApoE-AP.
It  is  worth noting  that  ApoE-AP is  active  on Gram-negative  strains  even if  it  interacts 
weakly with LPS. Therefore, LPS-binding, likely, is not necessary for antibacterial activity 
on Gram-negative  strains.  Moreover,  the  presence of  high concentrations  of  free LPS 
and/or capsular polysaccharides as alginates could scavenge and inhibit the antimicrobial  
activity of  ThrAP (as described for  other CAMPs that,  like ThrAP, bind these bacterial 
secretion products), whereas, ApoE-AP will retain its antimicrobial efficacy. On the other 
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hand, ApoE-AP, likely, will not be able to prevent septic shock. The data presented here 
strongly suggest that both from the structural and functional point of view ThrAP and ApoE-
AP  are  complementary.  This  conclusion  has  relevant  consequences  for  a  future 
pharmacological application of the two peptides.
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COMPUTATIONAL SECTION
3.8 Modelling of CAMPs by implicit solvation
An accurate representation of solvent is crucial in biological simulations in order to obtain  
meaningful  and realistic  results.  Simulations can be carried out  in presence of  explicit  
solvation,  but  the  relative  high  number  of  degree  of  freedoms  can  have  a  strong 
computational  cost,  and thus implicit  solvation,  that  approximate the effects  of  solvent 
through a potential of mean force, can reduce the computational complexity (Feig M. and 
Brooks C. L. III, 2004). A recent work from Huang A. and Stultz C. M. (2007) compared the 
local  energy minima of  a  small  peptide obtained with  explicit  solvation and with  three 
different models of implicit solvations, and found that all the different approaches mapped 
similar regions of the conformational space. Moreover, different authors developed solvent 
models for the simulations of peptides in lipid bilayers (Efremov R. G. et al., 1999a and b; 
Maddox M. W. and Longo M. L., (2002); Lazaridis T., 2003) and in pores (Mihajlovic M. 
and Lazaridis T., 2010; He Y. et al., 2013).
In  this  thesis,  the  influence  of  different  implicit  solvations  was  studied  on  a  panel  of  
experimental  structures of  CAMPs, by means of  the Monte Carlo  strategy,  in order to 
define  the  best  possible  conditions  which  preserve  the  initial  structure.  In  detail,  the 
simulation of each peptide was carried out in vacuum, water (with the effective energy 
function-1, EEF-1, developed by Lazaridis T. and Karplus M., (1999)), octanol (Hopfinger 
A. J. and Battershell R. D., 1976) and octanol with an attenuation of the solvation energy 
(0.5 x solvation energy and 0.25 x solvation energy). The last two conditions were studied 
with the aim of recreating a sort of “hybrid” ambient, “partially unpolar”, which could mimic  
a micellar environment and TFE solvation; NMR structures of CAMPs are in fact usually 
solved in presence of SDS or DPC micelles and TFE, as described in paragraph 1.3. The 
majority of  the  CAMPs selected for  this  study are helical  peptides which are,  usually, 
unordered in water and fold in the presence of micelles or TFE. This kind of peptides is  
very well studied, and several NMR structures are available. The only two exceptions in 
our set  are indolicidin  and tritrpticin,  that  adopt  a prevalently extended structure (PDB 
codes: 1G89 and 2I1D).
Tables  16-ABC  describe  the  results  of  the  structural  alignments  between  the  initial  
experimental structure and the lowest energy structure of the Monte Carlo ensemble in the 
different simulated environments, divided in three groups: structures solved in presence of 
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DPC micelles, SDS micelles and TFE.
Table  16-A:  RMSD  of  the  structural  alignments  between  the  peptide  structure  solved  in  the 
presence of DPC micelles and the lowest energy model obtained with the different simulations.
Structures solved in DPC micelles
Water 
solvation Vacuum
Octanol 
solvation
0.5x Octanol 
Solvation
0.25x Octanol 
Solvation
RP-1 (2RLH)
18 aa.
RMSD backbone (Å) 12.56 8.2 13.84 7.61 3.25
RMSD (portion (Å) / (4-16) 6.34(5-11) 1.66 /
(4-16) 3.83
(6-14) 1.21 (4-16) 1.57
Piscidin (2JOS)
22 aa.
RMSD backbone (Å) 12.06 4.35 17.78 7.27 9.55
RMSD (portion) (Å) / (8-21) 0.92 / (8-21) 0.94 (8-21) 8.57(8-14) 0.93
Indolicidin (1G89)
13 aa.
RMSD backbone (Å) 9.16 8.18 9.24 5.04 4.21
RMSD (portion) (Å) / (5-10) 1.29 / (5-10) 3.97(6-8) 1.47
(5-10) 1.84
(5-9) 1.48
Tritrpticin-1 (2I1D)
14 aa.
RMSD backbone (Å) 8.89 9.87 9.25 9.92 11.08
RMSD (portion) (Å) / / / / /
CM15 (2JMY)
15 aa.
RMSD backbone (Å) 13.22 8.14 14.07 7.62 10.93
RMSD (portion) (Å) / (2-9) 1.88(1-8) 1.26 /
(1-8) 1.57
(2-9) 1.21
(1-8) 3.35
(2-9) 4.50
(2-7) 1.4
Magainin-2 (2MAG)
23 aa.
RMSD backbone (Å) 10.9 12.98 13.89 6.55 5.68
RMSD (portion) (Å) / / / (5-18) 1.46(6-18) 1.46
(5-18) 1.93
(6-18) 1.27
LL-23 (2LMF)
23 aa.
RMSD backbone (Å) 11.98 10.13 14.43 3.20 3.31
RMSD (portion) (Å) / (5-20) 6.82 (11-18) 1.06 / (5-20) 1.25 (5-20) 1.38
PDB IDs are shown in brackets near the peptide's name.
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Table  16-B: RMSD  of  the  structural  alignments  between  the  peptide  structure  solved  in  the 
presence of SDS micelles and the lowest energy model obtained with the different simulations.
Structures solved in SDS micelles
Water 
solvation Vacuum
Octanol 
solvation
0.5x Octanol 
Solvation
0.25x Octanol 
Solvation
RP-1 (2RLG)
18 aa.
RMSD backbone (Å) 14.44 7.81 12.46 5.06 1.90
RMSD (portion) (Å) / (4-14) 4.51(5-10) 1.58 / (4-14) 1.24 (4-14) 1.03
Piscidin-1 analogue 
(2JON)
22 aa.
RMSD backbone (Å) 12.4 10.59 14.41 14.58 9.64
RMSD (portion) () (Å) /
(9-14) 2.38
(10-15) 2.38
(9-13) 2.29
/ (9-14) 2.56(10-15) 2.12
(10-15) 1.82
(9-14) 2.22
Indolicidin (1G8C)
13 aa.
RMSD backbone (Å) 8.44 8.22 7.82 4.88 5.45
RMSD (portion) (Å) / (5-9) 1.75 / (5-9) 1.77 (5-9) 1.73
Tritrpticin-1 (1D6X)
14 aa.
RMSD backbone (Å) 10.48 4.65 6.76 6.94 11.24
RMSD (portion) (Å) / (6-10) 2.37 (6-10) 4.19(5-8) 1.87 (6-10) 1.47 /
Latarcin-2a (2G9P)
26 aa.
RMSD backbone (Å) 8.69 4.66 19.14 7.06 6.55
RMSD (portion) (Å) / (13-22) 1.29 / (13-22) 0.63 (13-22) 0.69
LL-37 (2KFO)
37 aa.
RMSD backbone (Å) 8.03 6.11 13.06 7.10 8.55
RMSD (portion) (Å)
(13-30) 
3.35
(17-26) 
1.32
(13-30) 1.30 / (13-30) 1.59 (13-29) 1.28
(13-30) 2.24 (14-27) 
0.96
Piscidin-1 (2OJM)
22 aa.
RMSD backbone (Å) 10.45 8.73 16.31 1.75 9.76
RMSD (portion) (Å)
(5-19) 
5.82
(8-15) 
1.44
(5-19) 5.96
(10-20) 1.39 / (5-19) 0.87
(5-19) 6.04
(10-18) 1.51
PDB IDs are shown in brackets near the peptide's name.
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Table  16-C:  RMSD  of  the  structural  alignments  between  the  peptide  structure  solved  in  the 
presence of TFE and the lowest energy model obtained with the different simulations.
Structures solved in TFE
Water 
solvation Vacuum
Octanol 
solvation
0.5x Octanol 
Solvation
0.25x Octanol 
Solvation
Meucin-24 (2KFE)
24 aa.
RMSD backbone (Å) 10.1 4.39 11.8 7.7 6.22
RMSD (portion) (Å) (5-15) 1.01 (5-15) 1.33 / (5-15) 1.31 (5-15) 1.21
Fowlicidin-3 (2HFR)
27 aa.
RMSD backbone (Å) 17.15 5.88 23.11 9.29 6.31
RMSD (portion) (Å) / (9-20) 1.33 / (9-20) 1.49 (9-20) 1.3
Fowlicidin-2 (2GDL)
31 aa.
RMSD backbone (Å) 11.56 14.83 21.68 17.02 14.82
RMSD (portion) (Å) / / / / /
CAP18(106-137) (1LYP)
32 aa.
RMSD backbone (Å) 8.96 5.2 15.91 9.52 5.18
RMSD (portion) (Å) (7-21) 4.59(13-23) 1.46
(7-21) 2.24
(11-21) 1.36 /
(7-21) 1.54
(11-21) 1.10
(7-21) 3.08
(14-25) 1.62
Fowlicidin-1 (2AMN)
26 aa.
RMSD backbone (Å) 14.63 7.26 23.15 8.28 7.35
RMSD (portion) (Å) (10-16) 1.22 (7-17) 1.18 / (7-17) 1.67(8-17) 1.15 (7-17) 1.25
Phylloseptin-2 (2JP1)
19 aa.
RMSD backbone (Å) 12.13 6.82 8.51 4.95 6.45
RMSD (portion) (Å) / (5-13) 1.69(6-10) 1.42 / (5-13) 1.11 (5-13) 1.19
Ranatuerin-2CSa (2K10)
32 aa.
RMSD backbone (Å) 11.67 10.49 18.87 12.72 11.57
RMSD (portion) (Å) (14-25) 3.25(13-23) 1.44 14-25 (1.43) /
(14-25) 3.79
(15-22) 1.03
(14-25) 3.58
(12-21) 1.30
PDB IDs are shown in brackets near the peptide's name.
The results shown in tables 16-ABC point out that a relevant portion of the experimental 
structures solved in the presence of SDS or DPC micelles is preserved in simulations run 
using the “attenuated” octanol implicit solvation; to a lesser degree, also simulations in 
vacuum are able to preserve the experimental structure. As for the structures solved in 
presence of TFE, the results are less clear and both vacuum and the “attenuated” octanol 
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seem to provide similar results. Apparently, the “attenuated” octanol solvation is less able 
to preserve the conformation induced by TFE. TFE is a known strong helix inducer and the 
structures  obtained  in  this  solvent  are  likely  more  ordered  and  compact  than  those 
obtained in true micelles. The results obtained with magainin-2 are in good agreement with 
the simulations conducted by Efremov R. G. et al., (1999b), where the same peptide was 
studied in implicit water, an implicit membrane-like environment and vacuum. The most 
significant differences are in the conformer modelled in water, which completely looses 
secondary structure in our simulation, while instead still  retains helical  stretches in the 
cited work; they both share, however, a similar compact structure (Figure 21).
Figure  21: comparison  between  the  simulations  outputs  for  magainin-2.  In  green:  initial 
experimental structure (A) and models obtained in water (B), vacuum (C), octanol (D), 0.5x octanol 
(E)  and  0.25x  octanol  (F)  with  our  simulations;  in  grey:  models  obtained  in  the  membrane-
mimicking ambient (G), water (H) and vacuum (I) in the simulations run by Efremov R. G. et al., 
(1999b).  (The  initial  structure,  according  to  the  article,  perfectly  matches  the  model  G).  The 
molecules are depicted with the N-terminus up and the C-terminus down.
In order to further analyse the results of the modelling procedures we have determined 
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the number of residues in α-helix, the accessible surface area (ASA) and the volume of 
models and reference structures. The results are shown in table 17.
Table 17: helicity (Nα), accessible solvent area (ASA) and volume of the experimental structures 
and the lowest-energy conformers obtained in different environments.
Peptide Experimental structure
Water 
solvation Vacuum
Octanol 
solvation
0.5x 
Octanol 
Solvation
0.25x 
Octanol 
Solvation
Indolicidin (1G89)
13 aa.
Nα 0 0 0 0 0 0
ASA (Ǻ2) 1400 1261 1164 1500 1221 1206
Volume (Ǻ3) 1837 1907 1936 1810 1934 1925
Tritrpticin-1 (2I1D)
14 aa.
Nα 0 0 0 0 0 0
ASA (Ǻ2) 1161 1336 1097 1557 1341 1223
Volume (Ǻ3) 1852 1905 1956 1736 1834 1916
CM15 (2JMY)
15 aa.
Nα 11 0 9 0 6 7
ASA (Ǻ2) 1187 1270 1080 1495 1329 1109
Volume (Ǻ3) 1791 1880 1863 1780 1822 1895
RP-1 (2RLH)
18 aa.
Nα 13 0 8 0 8 11
ASA (Ǻ2) 1342 1744 1326 1703 1588 1539
Volume (Ǻ3) 2188 2122 2319 2122 2183 2224
Piscidin (2JOS)
22 aa.
Nα 10 0 19 0 13 14
ASA (Ǻ2) 1739 1611 1594 2041 1745 1513
Volume (Ǻ3) 2580 2779 2609 2424 2570 2670
Magainin-2 (2MAG)
23 aa.
Nα 18 0 16 0 14 12
ASA (Ǻ2) 1621 1637 1395 1992 1656 1613
Volume (Ǻ3) 2395 2632 2569 2391 2465 2514
LL-23 (2LMF)
23 aa.
Nα 18 10 15 0 20 21
ASA (Ǻ2) 1799 1962 1622 2270 1848 1783
Volume (Ǻ3) 2839 3020 2963 2709 2855 2875
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Indolicidin (1G8C)
13 aa.
Nα 0 0 0 0 0 0
ASA (Ǻ2) 1436 1224 1142 1045 1335 1222
Volume (Ǻ3) 1881 2039 1939 1993 1895 1947
Tritrpticin-1 (1D6X)
14 aa.
Nα 0 0 0 0 0 0
ASA (Ǻ2) 1306 1319 1179 1499 1335 1128
Volume (Ǻ3) 1868 1900 1939 1774 1848 1976
RP-1 (2RLG)
18 aa.
Nα 11 0 9 0 10 13
ASA (Ǻ2) 1358 1764 1351 1890 1563 1455
Volume (Ǻ3) 2143 2247 2322 2076 2258 2366
Piscidin-1 analogue (2JON)
22 aa.
Nα 5 4 13 0 8 13
ASA (Ǻ2) 1690 1786 1495 2125 1815 1589
Volume (Ǻ3) 2622 2764 2744 2523 2640 2713
Latarcin-2a (2G9P)
26 aa.
Nα 17 5 15 0 15 18
ASA (Ǻ2) 1941 2105 1831 2415 2042 1991
Volume (Ǻ3) 2995 3062 3045 2715 2882 2976
Piscidin-1 (2OJM)
22 aa.
Nα 19 13 15 0 18 17
ASA (Ǻ2) 1696 1533 1477 2038 1652 1523
Volume (Ǻ3) 2581 2797 2687 2398 2628 2643
LL-37 (2KFO)
37 aa.
Nα 29 25 28 0 30 25
ASA (Ǻ2) 2940 2998 2598 3519 2807 2629
Volume (Ǻ3) 4570 4661 4682 4311 4597 4777
Phylloseptin-2 (2JP1)
19aa.
Nα 13 7 10 0 13 12
ASA (Ǻ2) 1420 1256 1250 1666 1415 1362
Volume (Ǻ3) 2169 2290 2210 1981 2099 2140
Meucin-24 (2KFE)
24 aa.
Nα 19 12 18 6 17 16
ASA (Ǻ2) 1826 1882 1698 2058 1782 1661
Volume (Ǻ3) 2731 2775 2735 2655 2749 2767
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Fowlicidin-1 (2AMN)
26 aa.
Nα 11 5 17 0 14 14
ASA (Ǻ2) 2077 2299 1935 2599 2079 2063
Volume (Ǻ3) 3218 3281 3187 2952 3208 3209
Fowlicidin-3 (2HFR)
27 aa.
Nα 12 9 17 0 12 16
ASA (Ǻ2) 2095 2156 1901 2487 2051 1964
Volume (Ǻ3) 3123 3127 3154 2908 3153 3146
Fowlicidin-2 (2GDL)
31 aa.
Nα 9 4 15 0 12 10
ASA (Ǻ2) 2466 2859 2128 3130 2564 2382
Volume (Ǻ3) 4035 3852 4164 3577 3823 4062
CAP18(106-137) (1LYP)
32 aa.
Nα 26 12 25 0 25 26
ASA (Ǻ2) 2561 2795 2425 3191 2473 2500
Volume (Ǻ3) 3997 3882 4030 3620 4081 3899
Ranatuerin-2CSa (2K10)
32 aa.
Nα 21 16 18 10 28 24
ASA (Ǻ2) 2057 2238 1991 2515 2127 2088
Volume (Ǻ3) 3383 3356 3383 3193 3288 3282
Peptides are coloured according to their experimental origin, as in tables 16-ABC.
The analysis  of  the  data  in  table  17  shows that  almost  all  the  structures  obtained in 
vacuum have the lowest ASA, maintain a good amount of helicity and often display more 
residues in α-helix than the experimental structures. In general, these models deviate from 
the  experimental  conformation  to  a  greater  extent  than  the  structures  obtained  in 
attenuated octanol, except for the structure in TFE; in this case, as described before, the 
two strategies give similar results. The highest ASA is instead found for the conformers 
modelled in octanol, where the secondary structure is completely lost and all the residues 
are exposed, thus inducing a simulated “denaturation”. Helix structure is lost also in water,  
in particular for peptide structures determined in DPC; moreover, ASA in water is in some 
cases lower than the starting experimental value. These results are due to the fact that 
water  solvation  reproduces  the  hydrophobic  effect,  thus  inducing  the  “collapse”  of 
hydrophobic  residues.  Models  obtained  using  attenuated octanol  are  characterized  by 
values of ASA and levels of helicity intermediate between values of the initial structures 
and values of the vacuum models, thus giving a more realistic picture than in vacuum.
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As a  control,  we  also  examined  two  β-sheets  peptides,  human β-defensin  1  and  pig 
protegrin-1,  whose NMR structure has been solved in  water.  These peptides possess 
disulphide bridges which make their structures more rigid with respect to helical peptides 
so  that,  whereas  helical  peptides  are  structured  only  in  membranes  (or  membrane 
mimetics), defensins and protegrins are structured also in water. Therefore we modelled 
human β-defensin 1 and pig protegrin-1 in water, using the NMR structures solved in water 
as initial structures. The models obtained were very similar to the experimental structures 
(data not shown).
The main conclusions of our analysis are:
I. the attenuated implicit octanol solvation provides the best results when models are 
compared to structures obtained with SDS or DPC micelles;
II. modelling in vacuum and sometimes attenuated implicit octanol solvation provide 
the best results when models are compared to structures obtained in TFE;
These results  will  be useful  for  the development of  non-demanding  ab initio modelling 
procedures of CAMPs in membrane-like environments.
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4. CONCLUSIONS
The work presented here is inserted in the wide field of research on cationic antimicrobial  
peptides (CAMPs), molecules thoroughly studied for their potential pharmacological use. 
Employing bioinformatic, experimental and computational approaches we have developed 
a panel of tools for the identification, production and characterization of new CAMPs.
Sequence studies permitted to define a novel scoring system capable of locating, with very 
good accuracy, putative CAMP-like fragments inside protein sequences. The main novelty 
of our method is the introduction in the scoring of the putative CAMPs of strain dependant 
variables which allow to search putative CAMPs particularly active against the strains of 
interest. A preliminary in silico validation shows that our scoring system accurately detect 
all  the  known  antimicrobial  fragments  in  proteins.  We  are  currently  automating  the 
procedure in  collaboration with  Prof.  O.  Crescenzi  (Department  of  Chemical  Sciences, 
University of Naples, Federico II) in order to analyze large sets of proteins, like for example 
human secretome and hence to identify potential new human CAMPs. Preliminary results 
indicate that a very high number of potential new CAMPs are contained in our extracellular 
proteins,  thus  suggesting  that  the  phenomenon  of  “cryptic”  CAMPs  is  much  more 
widespread than currently believed.
Parallely we have developed a novel fusion construct for the recombinant expression of 
CAMPs. This fusion construct allows to obtain pure peptides in high yield with just a single 
chromatographic step and mild conditions for the chemical cleavage of the peptide from 
the carrier. Moreover, it is very versatile allowing the production of relative long peptides 
(40-50 aa.) and  15N/13C labeled peptides, thus providing an interesting alternative to the 
expensive chemical synthesis. Our fusion system will make easier the characterization of 
the newly identified CAMPs.
Two  human  CAMPs,  ThrAP  and  ApoE-AP,  respectively  located  in  thrombin  and 
apolipoprotein E, were produced using our fusion construct. Their biological and structural 
characterization revealed that  the two peptides possess complementary molecular and 
biological  features,  in  fact,  ApoE-AP displays  a  stronger  antibacterial  activity  and  no 
binding to CAMP-scavenging bacterial molecules like LPS and alginate, whereas ThrAP, 
characterized by a weaker antibacterial activity, is instead able to bind LPS and thus could 
prevent septic shock. Our data clearly suggest the two peptides are non equivalent from 
the pharmacological point of view and further widen the possible application of CAMPs in  
medicine.
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Finally, the last part of this thesis focuses on preliminary studies of the structural modelling 
of CAMPs. Monte Carlo simulations performed using different implicit solvation functions 
allowed to  define  in  silico conditions which  reproduce with  good accuracy the starting 
experimental structures. These data will be the stating point for the development of  ab 
initio strategies for the prediction of CAMPs' structures.
Concluding, we believe that the methods we have developed will significantly stimulate the 
research in  the  field  of  antimicrobial  peptide  and the  development  of  pharmacological 
strategies based on them.
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APPENDIX
Antibacterial activity of basic and disulphide-rich proteins
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5. BRIEF INTRODUCTION AND AIM
Lysozyme  from  Gallus  gallus and  human  RNase 4  are  two  proteins  which  share  an 
abundance of basic residues and cysteines and a relative small weight (around 14 kDa), 
as shown in table 18.
Protein Primary structure Isoelectric point
Gallus gallus 
lysozyme
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNT
QATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPCS
ALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQA
WIRGCRL
9.32
Human RNase 4
QDGYYQRFMRQHLHVEETGGSDRYPNLMMQRRRMTLYHC
CRFNTFIHEDIWNIRSICSTTNIQCKNGKMNCHEGVVKVTDC
RDTGSSRAPNCRYRAIASTRRVVIACEGNPQVPVHFDG
9.05
Table 18: primary structures of Gallus gallus lysozyme (UniProt ID: P00698) and human RNase 4 
(UniProt ID: P34096); basic residues, hydrophobic residues and cysteines are respectively colored 
in blue, green and yellow.
Lysozyme is an antibacterial  protein which cleave the bacterial  cell  wall;  it  retains the 
antibacterial property also when the enzymatic activity is abolished by heat denaturation 
(During K. et al., 1999) or by point mutations (Ibrahim H. R. et al., 2001a), and CAMP-like 
fragments are released upon digestion with pepsin (Ibrahim H. R. et al., 2005; Ibrahim H. 
R.  et  al.,  2001b).  These  studies  point  out  that  the  bactericidal  activity  can  also  be 
independent  from  the  catalytic  one  and  the  tertiary  structure,  and  this  peculiar 
phenomenon has been demonstrated for many different proteins as described in detail in 
the introduction of this thesis.
Several human ribonucleases are active  protagonists of the immune system, exploiting 
their defense activity in various districts of the human body (Sorrentino S., 2010). Also for 
these proteins, the antibacterial activity can be separated from the enzymatic one, which 
consists of RNA degradation, and experimental evidences, which enforce this hypothesis, 
were  already  found  for  some  human  ribonucleases  (Torrent M.  et  al.,  2013) and 
homologous ribonucleases from Gallus gallus (Nitto T. et al., 2006), Danio rerio (Pizzo E. 
et al., 2011; Zanfardino A. et al., 2010) and Salmo salar (Pizzo E. et al., 2008).
In conclusion, the presence of one or more potential CAMP-like regions in lysozyme and 
bactericidal RNases seems to be the major requisite for their activity against pathogens.
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The main aim of this experimental work is to verify if  Gallus gallus lysozyme and human 
ribonuclease  4  can  be  turned  into  more  efficient  carrier  of  antimicrobial  regions  if 
maintained in a stable denatured and reduced form through the alkylation of cysteines; two 
works (Pizzo E.  et al.,  2008; Pizzo E.  et al., 2011) show, in fact,  that the antibacterial 
activity  of  RNases  from  Danio  rerio and  Salmo  salar is  enhanced  when  they  are 
administered in a denaturated form, while Schroeder B. O.  et al., (2011) discovered that 
the  antibacterial  potential  of  human β-defensin  1  is  augmented  after  the  reduction  of 
disulphide  bridges.  Whereas Gallus  gallus lysozyme's  antibacterial  activity  and  cryptic 
CAMPs are already known, the biological activity of human RNase 4 is still unclear, and a 
possible bactericidal role is just an hypothesis (Sorrentino S., 2010).
6. MATERIALS AND METHODS
6.1 Materials
Ampicillin, bovine serum albumin (purity > 97%),  IPTG, urea, DTT, Ellman's reagent, L-
cysteine,  guanidine  chloride,  agar  and  the  alkylating  agents  (3-bromopropylamine 
hydrobromide,  iodoacetamide and 4-vinylpyridine)  were  purchased from  Sigma-Aldrich. 
Gallus gallus lysozyme with a grade of purity of 95% was purchased from Sigma-Aldrich 
and  used  without  further  purification.  Trypton  and  yeast  extract  were  purchased  from 
Becton  Dickinson.  Sodium  chloride  and  acrylamide  (30%  stock  solution)  were  from 
Applichem.  Trifluoroacetic  acid  and  acetonitrile  used  for  HPLC  were  purchased  from 
Romil.
6.2 General procedures
Cell  transformation  and  growth  medium  preparation  were  performed  according  to 
Sambrook J. et al., (1989). SDS-PAGE was carried out according to Laemmli U. K. (1970). 
Protein concentrations were determined by  the method of Bradford, using BSA as the 
standard (Bradford M. M., 1976) and by UV spectroscopy using the theoretical, sequence-
based extinction coefficients in table 19 (Gill S. C. and von Hippel P. H.,1989).
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Table 19: sequence-based extinction coefficients of the variants of  Gallus gallus lysozyme and 
human RNase 4.
Extinction coefficient of the 
native form (M-1 cm-1)
Extinction coefficient of the 
alkylated form (M-1 cm-1)
hRNase 4 11960 11460
Gallus gallus lysozyme 37970 37470
The content of  free cysteines after the alkylation reactions was assessed according to 
Ellman G. L. (1959).
6.3 Heterologous expression and preliminary purification of human
RNase 4
Escherichia coli BL21(DE3) cells (AMS Biotechnology) were used for recombinant protein 
expression; cells transformed with pET 22b(+)-hRNase 4 were grown in 1 liter of Luria-
Bertani medium containing ampicillin (0.1 mg/mL). When the culture reached an A 600 nm of 
0.7  OD unit,  protein expression was induced by the addition of 0.4 mM IPTG and the 
bacterial culture was grown over-night. Cells were harvested by centrifugation (7000 rpm, 
4°C, 15', JA-14 rotor, Beckman) and pellets were lysed by sonication in 20 mL of lysis  
buffer  [50  mM  Tris-acetate,  pH  8.4,  containing  10  mM  EDTA and  protease  inhibitor 
(Roche)] in an ultrasonic liquid processor (Misonix Ultrasonic Processor XL)  at 20 kHz 
with 30'' impulses, each followed by a 30'' rest, for a 15' total time. The suspension was 
then centrifuged at 12000 rpm for 60' at 4°C (JA-25.50 rotor, Beckman). The inclusion 
bodies  were  freed  from  membrane  proteins  by  two  washes  in  0.1  M  Tris-acetate, 
containing 10 mM EDTA, 2 % Triton X-100 and 2 M urea, followed by repeated washes in 
0.1 M Tris-acetate pH 8.4, containing 10 mM EDTA, to eliminate traces of Triton and urea.  
This procedure eliminated several contaminant proteins and cellular debris entrapped in 
inclusion body pellets.
Inclusion bodies were then dissolved in 0.1 M Tris-acetate pH 8.4, 10 mM EDTA, 6 M 
GuHCl  and 25 mM DTT,  purged with  N2,  and incubated at  37°C for  3  h.  The protein 
solution was acidified to pH 5 with glacial acetic acid and dialyzed over-night against 0.1 M 
acetic acid (pH 3) at 4°C. Any insoluble material was removed by centrifugation (12000 
rpm, 30', 4°C, rotor JA-25-50, Beckman) and the supernatant, containing the RNase in the 
completely reduced form, was lyophilized.
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6.4 Preparation of denatured and reduced Gallus gallus lysozyme
Gallus gallus lysozyme (lyophilized powder) was dissolved in 0.1 M Tris-acetate pH 8.4, 10 
mM EDTA, 6 M GuHCl and 25 mM DTT at a final concentration of about 14 mg/mL, purged 
with N2, and incubated at 37°C for 3 h. The protein solution was acidified to pH 5 with  
glacial acetic acid, dialyzed over-night against 0.1 M acetic acid (pH 3) at 4°C and finally  
lyophilized.
6.5 Alkylation of cystein residues
The optimal conditions for the alkylation reactions are shown in table 20. The lyophilized 
protein was dissolved in the adequate reaction buffer at a final concentration of 1 mg/mL, 
the appropriate amount of reactive was immediately added and the solutions were finally 
purged with N2. At the end of incubation, the reactions were stopped by the addition of β-
mercaptoethanol  (at  a  final  concentration  double with  respect  to  the alkylating agent), 
acidified to pH 5 with glacial acetic acid and exhaustively dialyzed against 20 mM AMAC, 
pH 4.5, at 4°C. Any insoluble material was removed by centrifugation (12000 rpm, 30',  
4°C, rotor JA-25-50, Beckman).
Table 20: optimal conditions for the alkylation of cysteine residues.
Alkylating agent Reaction buffer Incubation
Ratio 
cysteine/alkylating 
agent
3-bromopropylamine 
hydrobromide
(BPA)
Tris HCl 0.2 M, pH 9.5, 
EDTA 7 mM,GuHCl 6 M
24 hours
37°C
1:108
Iodoacetamide
(IAA)
MES 0.2 M, pH 6.1, 
EDTA 7 mM, GuHCl 6 M
Over-night
25°C
1:10
4-vinylpyridine
(VP)
Tris HCl 0.1 M, pH 8.5, 
EDTA 7 mM, GuHCl 6 M
Over-night
25°C
1:36
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6.6 High pressure liquid cromatography (HPLC)
The  chromatography  was  conducted  on  a  Perkin-Elmer  series  200  instrument  and 
monitored at λ 278 nm. The alkylated variants of hRNase 4 were loaded on a reverse-phase 
C-4 column (Phenomenex) equilibrated in 100% solution A (composed of 5% acetonitrile 
(v/v) and 0.1% trifluoroacetic acid (v/v)). The column was eluted with a gradient in which 
the  concentration  of  solution  B  (composed  of  95%  acetonitrile  (v/v)  containing  0.1% 
trifluoroacetic acid (v/v)) was raised in 70'.
6.7 Acetic acid-urea Polyacrylamide Gel Electrophoresis
The electrophoretic migration of the alkylated variants of the two proteins was checked on 
a 12% polyacrilamide-gel containing 2 M urea and 50 mM acetic acid-NaOH, pH 4.5. The 
loading buffer contained 2 M urea, 10% glycerol, 50 mM acetic acid-NaOH, pH 4.5, and 
0.01% bromophenol blu. The electrophoretic run was conducted for 3 hours at 150 V using 
50 mM acetic acid-NaOH, pH 4.5 with 2 M urea as running buffer.
6.8 Bactericidal assays
See paragraph 2.9
7. RESULTS
7.1 Preparation of the alkylated variants of Gallus gallus lysozyme
The alkylation  of  cysteines permits  to  maintain  the  protein  in  a  stable  denatured and 
reduced  form  and  to  modulate  protein  net  charge  and/or  hydrophobicity. The  variant 
modified  with  3-bromopropylamine  (Lyz-PA),  in  fact,  receives eight  additional  positive 
charges,  whereas the  variant  modified  with  4-vinylpyridine  (Lyz-PE)  contains eight 
aromatic groups which act as weak bases with a pKa ≈ 6. Finally, iodoacetamide adds a 
polar carboxamidomethyl group to each cysteine (Lyz-CAM) (Figure 22).
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Figure 22: chemical structures of the alkylating agents: iodoacetamide (A),  3-bromopropylamine 
(B) and 4-vinylpyridine (C); the leaving group, the group that binds to cysteine and the cysteine 
residue are respectively coloured in green, red and blue.
The three alkylated variants were produced as described in material and methods and the 
free cysteines content, assessed with the Ellman test, was lower than 10%.
7.2 Acetic acid-urea Polyacrylamide Gel Electrophoresis of the alkylated  
variants of Gallus gallus lysozyme
Gallus gallus lysozyme's  alkylated variants were analysed through an acetic  acid-urea 
PAGE at pH 4.5. In these conditions, the velocity of migration depends on three factors: 
molecular weight,  the compactness of the structure and net charge. A denatured protein 
maintains  the  same  net  charge  and  molecular  weight  of  the  native  form,  but  is  less 
compact and thus has a lower velocity of  migration.  As shown in figure 23,  lysozyme 
variants  display a  reduced rate of migration compared to native lysozyme,  as expected. 
The discrepancy between the variants can be explained considering that in Lyz-PE the 
pyridinic  groups are not  completely protonated at  pH 4.5.  In  conclusion,  the  chemical  
modifications have a strong impact on lysozyme structure and the presence of an almost  
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single  electrophoretic  band  for  each  variant  suggests  that  they  are  homogeneously 
modified.
    1   2 3       4
Figure  23:  12%  acetic  acid-urea PAGE at  pH  4.5  of  the  alkylated  variants  of  Gallus  gallus 
lysozyme. Lane 1: native lysozyme (5 μg); lane 2: lyz-PA (5 μg); lane 3: lyz-PE (5 μg); lane 4: lyz-
PA (5 μg).
7.3 Bactericidal activity of the alkylated variants of Gallus gallus lysozyme
As  described  in  the  introduction,  the  bactericidal  activity  of  native  lysozyme  can  be 
attributed both to its enzymatic activity and to the presence of CAMP-like regions in its 
primary  structure;  lysozyme's  alkylated  variants,  instead,  have  completely  lost  their 
enzymatic activity (data not shown), and thus their bactericidal action can be explained 
only  considering  the  presence  of  antimicrobial  determinants  in  their  sequence.  The 
alkylated variants show levels of activity comparable and in some cases superior to the 
native form (Figure 24).
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Figure 24:  antibacterial  assays of native  Gallus gallus lysozyme and of two variants at a final 
concentration of 3 μM against Staphilococcus aureus ATCC 6538P. The relative error was always 
lower than the 10% of the measure.
7.4 Over-expression, alkylation and purification of human ribonuclease 4
The  results  observed  with  Gallus  gallus lysozyme  point  out  that  the  irreversible 
denaturation obtained through the chemical modifications of cysteines seems to be a valid 
strategy to enhance the antimicrobial potency of basic and disulphide-rich proteins and, 
consequently,  the same study was performed with human ribonuclease 4. It  should be 
noted that this protein, due to the human origin, could be more useful in the clinical field  
than the chicken protein.
The expression of human ribonuclease 4 was conducted as described in materials and 
methods and its level was analyzed by SDS-PAGE 15% (Figure 25).
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Figure 25: 15% SDS-PAGE with the analysis of the expression of hRNase 4.  Lane 1: induced 
culture (0.126 OD); lane 2: RNase A ( kDa, 5 μg); lane 3: non-induced culture (0.126 OD).
A densitometric analysis permitted to estimate a protein yield of about 20 mg per liter of 
culture. Cells were harvested by centrifugation and then lysed by sonication; the lisate was 
centrifuged in order to separate the soluble fraction from the inclusion bodies. The protein 
was expressed only in the insoluble fraction (data not shown) and was partially purified 
from membrane debris and other contaminants by several washes of the inclusion bodies 
with a buffer containing a detergent (Triton X-100) and a mild denaturing agent (Urea 2 M); 
aliquots of the supernatants of the washes were analyzed on SDS-PAGE 15% (Figure 26, 
lanes 3-7), in order to check any possible loss of protein during the preliminary purification. 
Inclusion  bodies  were  finally  dissolved  in  a  denaturing  and  reducing  buffer  and  were 
extensively  dialyzed  against  a  solution  of  acetic  acid  0.1  M  (pH  3),  with  the  aim  of 
maintaining the protein in a denatured and reduced state for the next step of chemical 
modification. An aliquot of the partially purified protein after dialysis was analyzed on SDS-
PAGE 15% (Figure 26, lane 8).
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Figure 26: 15% SDS-PAGE of the preliminary purification of hRNase 4. Lane 1: molecular weight 
markers (Color-Burst,  Sigma Aldrich);  lane 2:  soluble fraction after cell  lysis (5 μL);  lanes 3-7: 
supernatant of the five inclusion bodies washes (5 μL); lane 8: partially purified hRNase 4 (5 μg).
The protein was finally lyophilized and the three different variants (hRNase 4-PA, hRNase 
4-CAM and  hRNase 4-PE) were prepared as described in materials and methods and 
were finally purified to homogeneity by means of HPLC; chromatograms are shown in 
figure 27, whereas the SDS-PAGE analysis is shown in figure 28.
Figure 27: HPLC chromatograms of hRNase 4-CAM (black line), hRNase 4-PA (green line) and 
hRNase 4-PE (blue line).
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Figure  28:  15% SDS-PAGE of  the  purification  of  hRNase  4-CAM.  Lane 1:  molecular  weight 
markers (Color-Burst, Sigma Aldrich); lane 2: protein after HPLC (5 μg).
The free cysteine content was lower than 10% for all the modified forms of hRNase 4.
7.5 Acetic acid-urea Polyacrylamide Gel Electrophoresis of the alkylated  
variants of human ribonuclease 4
The  alkylated  variants  of  hRNase  4  showed  a  pattern  of  electrophoretic  migration 
analogous to the lyosozyme's modified forms, as shown in figure 29. Due to the difficulties 
in obtaining the native variant of hRNase 4, the migration of the denatured forms was 
compared to the migration of native RNase A.
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Figure 29: 12% acetic acid-urea PAGE at pH 4.5 of the alkylated variants of hRNase 4. Lane 1: 
native RNase A (5 μg); lane 2: hRNase 4-PA (5 μg); lane 3: hRNase 4-PE (5 μg); lane 4: hRNase 
4-PA (5 μg); lane 5: hRNase 4-CAM (5 μg).
The modified form with the highest net charge, hRNase 4-PA, migrates faster than the 
other two modified forms, but more slowly than the native form, which is characterized by a 
more compact structure. In conclusion, as observed for the alkylated variants of lysozyme, 
the alklylation procedures did not generate a relevant heterogeneity of modified forms.
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7.6 Bactericidal activity of the alkylated variants of human ribonuclease 4
The first antibacterial assays of the ribonuclease 4 variants hRNase 4-PA and hRNase 4-
PE were conducted on different  lab strains, including both Gram-negatives and Gram-
positives; the results are displayed in figure 30.
Figure 30: antibacterial assays of two variants of human ribonuclease 4 at a final concentration of 
0.3  μM  against  Staphilococcus  aureus ATCC  6538P  (yellow),  Bacillus  subtilis  PY79  (red), 
Pseudomonas aeruginosa PAO1 (green) and Escherichia coli DH5α (blue). The relative error was 
always lower than the 10% of the measure.
Both  variants  display an antibacterial  activity,  but  it  is  not  possible  to  define  the  best 
modification, as the level of activity seems to depend on the bacterial strain. This result is 
confirmed  by  the  antibacterial  essays  conducted  on  different  clinical  isolates  of 
Pseudomonas  aeruginosa,  kindly  provided  by  D.  Alessandra  Bragonzi  (San  Raffaele 
Hospital, Milan), which are shown in figure 31.
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Figure 31: antibacterial assays of two variants of human ribonuclease 4 at a final concentration of 
0.3 μM against three clinical isolates of Pseudomonas aeruginosa: AA2 (light green), PA14 (green) 
and BT72 (olive green). The relative error was always lower than the 10% of the measure.
8. CONCLUSIONS
The work reported here demonstrates that basic and disulphide-rich proteins with known 
or  putative  CAMP-like  regions  can  be  easily  produced  and  maintained  in  a  stable 
denatured  and  reduced  form,  with  the  possibility  of  obtaining  variants  with  different 
biological  actions  by  simply  modifying  the  chemical  nature  of  the  group  attached  to 
cysteines. The denatured forms are active on both lab strains and clinical isolates from 
lungs of cystic fibrosis patients, and thus are promising therapeutic agents. The strategies 
described here can be applied to other basic and disulphide-rich human proteins and, 
moreover,  other modifying agents  could be tested, in order to obtain a broad panel of 
antimicrobial and pharmacologically relevant proteins.
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